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ABSTRACT 
Enzymes which regulate the metabolic reactions for sustaining all living 
things, are the engines of life. The discovery of molecules that are able to control 
enzyme activity is of great interest for therapeutics and the biocatalysis industry. 
Peptides are promising enzyme modulators due to their large chemical diversity 
and the existence of well-established methods for library synthesis.  
Microarrays represent a powerful tool for screening thousands of 
molecules, on a small chip, for candidates that interact with enzymes and 
modulate their functions. In this work, a method is presented for screening high-
density arrays to discover peptides that bind and modulate enzyme activity. A 
viscous polyvinyl alcohol (PVA) solution was applied to array surfaces to limit the 
diffusion of product molecules released from enzymatic reactions, allowing the 
simultaneous measurement of enzyme activity and binding at each peptide 
feature. For proof of concept, it was possible to identify peptides that bound to 
horseradish peroxidase (HRP), alkaline phosphatase (APase) and β-
galactosidase (β-Gal) and substantially alter their activities by comparing the 
peptide-enzyme binding levels and bound enzyme activity on microarrays. 
Several peptides, selected from microarrays, were able to inhibit β-Gal in solution, 
which demonstrates that behaviors selected from surfaces often transfer to 
solution. A mechanistic study of inhibition revealed that some of the selected 
peptides inhibited enzyme activity by binding to enzymes and inducing 
aggregation.  
PVA-coated peptide slides can be rapidly analyzed, given an appropriate 
enzyme assay, and they may also be assayed under various conditions (such as 
temperature, pH and solvent). I have developed a general method to discover 
  ii 
molecules that modulate enzyme activity at desired conditions. As 
demonstrations, some peptides were able to promote the thermal stability of 
bound enzyme, which were selected by performing the microarray-based 
enzyme assay at high temperature. For broad applications, selected peptide 
ligands were used to immobilize enzymes on solid surfaces. Compared to 
conventional methods, enzymes immobilized on peptide-modified surfaces 
exhibited higher specific activities and stabilities. Peptide-modified surfaces may 
prove useful for immobilizing enzymes on surfaces with optimized orientation, 
location and performance, which are of great interest to the biocatalysis industry.  
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CHAPTER 1: GENERAL INTRODUCTION 
ABSTRACT 
In this chapter, the basic concepts of enzymes and enzyme modulation 
are introduced. The general methods for discovering molecules that modulate 
enzyme function are briefly summarized. This chapter discusses the potential 
applications of peptide-based molecules in ligand development and drug 
discovery. Finally, microarray-based profiling of protein interactions and enzyme 
activity is described, which is closely related to the subsequent chapters. 
Enzymes 
The metabolism of living systems involves complex synthetic pathways 
with numerous multi-step reactions that possess extraordinary yields and 
specificities1-2. In these complex systems, enzymes play key roles as catalysts 
and are essential to biological functions. No enzymes, no life. In general, 
enzymes are proteins or protein-based molecules that speed up chemical 
reactions in living organisms.3-4 Enzymes do not initiate reactions with 
unfavorable changes in free energy and that would not naturally occur. They 
accelerate reactions toward equilibrium with rate enhancements of 106 – 1017, 
compared to uncatalyzed reactions.5-6 In Figure 1, an enzyme catalyzes a 
reaction by first binding to the substrate molecules, then lowering the activation 
energy in the microenvironment created at the active site, converting substrate to 
product molecules, releasing the product molecules from the active site, and 
being ready to accept the next substrate.7   
Most enzymes are globular proteins and consist of one or several poly 
peptide chains ranging from just 60 amino acid residues8 to over 2,500 residues 
in length.9 For a given enzyme, the polypeptide chains are folded into a specific 
2 
three-dimensional structure, under physiological conditions, forming an active 
site which generally consists of 3-4 key amino acids.10-11 In Figure 2a, the protein 
folding of ketosteroid isomerase is shown as an example. In its active site, an 
enzyme catalyzes a reaction by favoring binding to the substrate transition state, 
which is a high-energy, unstable arrangement of atoms formed during a reaction, 
and essential for product generation (Figure 2b).12 As shown in Figure 3, an 
enzyme stabilizes the transition state of the substrate and lowers the energy 
barrier (activation energy), making the reaction much more likely to occur. 
Recently, catalytic nucleic acids (RNA or DNA-based) have been discovered 
which catalyze some chemical reactions, like nucleic acid cleavage or 
synthesis.13  
 
 
Figure 1. Description of the basic processes of enzyme catalysis.14 
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a 
b 
 
Figure 2. Example of (a) an enzyme folding from a linear poly peptide chain to a 
3-D structure and (b) stabilization of the substrate transition state and conversion 
of substrate to product. The example enzyme is ketosteroid isomerase.12 
 
 
b
a
 
Figure 3. Gibbs free energy change for (a) an uncatalyzed reaction and (b) a 
catalyzed reaction.  ∆GN‡ and ∆GE‡ indicate the activation energy required to 
induce the transition for the uncatalyzed (red) and catalyzed (blue) reactions, 
respectively.3,15 
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Enzymes are crucial in maintaining health. Many diseases are related to 
the malfunction of certain key enzymes, for instance, beta-secretase has recently 
been implicated in the early development of Alzheimer's disease.16 Many drugs 
target specific enzymes, either inhibiting or activating them.17-18 Enzymes, 
themselves, can also be used as therapeutic drugs. For example, Adagen® is a 
bovine adenosine deaminase that is used to treat a type of severe combined 
immunodeficiency disease.19  
The strong catalytic efficiency and high specificity of enzymes make them 
ideal candidates for industrial applications. The use of enzymes dates back 
several thousand years, when ancient Egyptians were making beer from flour, 
although they were likely unaware of the concept of enzymes.20 In 1897, Eduard 
Buchner discovered the ability of yeast extracts to ferment sugar as the start of 
using purified enzymes in industry.21 Today, enzymes are widely used in 
detergents and paper manufacturing as well as food, textile, fuel and alcohol 
production.22 More and more organic synthesis processes are starting to use 
enzymes as catalysts to obtain higher yields and regioselectivity.23-24 The use of 
enzymes in synthesis may reduce the use of organic solvents with similar 
product yields and selectivity as traditional organic synthesis, and will be very 
important for green chemistry.25-26   
Most enzymes used today originally come from Nature or have evolved 
from naturally-existing enzymes. High-throughput screening of living organisms 
for interesting catalytic targets is still one of the major sources of novel 
enzymes.27-28 Directed evolution, which mimics Darwinian evolution on an 
accelerated time-scale, has been widely used to discover new enzyme variants 
by combining random mutagenesis and recombination with screening or 
5 
selection for desired protein target functions.29-30 Site-directed mutagenesis is 
used as a probe to study enzyme structure and function.31-33 Szostak’s group 
recently reported the selection and evolution of an enzyme from a partially-
randomized, non-catalytic scaffold using mRNA display.34  
Enzymes catalyze reactions by stabilizing the substrate transition state. 
Catalytic antibodies that bind to transition-state analogues have been developed 
as new enzymes with desired functions (Figure 4).35-36 Recent developments in 
rational protein design make it possible to design novel enzymes completely 
through computational approach. Baker’s group reported the design of an 
artificial enzyme catalyzing the Diels-Alder reaction, which was predicted from 
the computational analysis of protein binding to the transition state of the reaction 
(Figure 5).37  
 
 
Figure 4. The generation of a catalytic antibody that binds to a Transition-State 
Analogue (TSA) to promote specific catalytic activities.    
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Figure 5. Computational design of an enzyme that stabilizes the transition state 
and catalyzes the stereoselective Diels-Alder reaction. 
Enzyme Modulation 
Enzyme modulation plays an important role in biological metabolism38, 
and regulates metabolic pathways through inhibition or activation of key 
enzymes. Most specific enzyme inhibition happens through binding to small-
molecule inhibitors, which either stop substrates from entering enzyme active 
sites, or hinder enzymes from catalyzing their respective reactions. In some 
special cases (e.g. cellular enzyme inhibitors), proteins can also act as enzyme 
inhibitors, like trypsin inhibitor39 and  ribonuclease inhibitor.40 Inhibitor binding can 
be reversible or irreversible. Reversible inhibitors bind to specific sites on 
enzymes through non-covalent interactions, such as hydrogen bonding, 
hydrophobic interactions and charge interactions. Non-covalent interactions 
between enzymes and reversible inhibitors dissociate when competitor 
molecules are added to the system or when the system undergoes dialysis, and 
enzyme activity is thereby recovered.    
Generally, there are four types of reversible enzyme inhibitions which are 
classified according to their kinetics: competitive inhibition, non-competitive 
inhibition, uncompetitive inhibition and mixed inhibition,3 as shown in Figure 6. A 
competitive inhibitor and the substrate molecule cannot bind to an enzyme at the 
7 
same time (Figure 7a); usually because the inhibitor possesses the similar 
structure as the substrate and binds to the enzyme active site (good inhibitors 
bind to enzymes stronger than substrates). This results in an increased apparent 
Km with unchanged Vmax (Figure 6b). In Figure 7b, a noncompetitive inhibitor 
generally binds to an enzyme at sites other than the active site, and inhibits the 
enzyme activity. It does not affect the ability of enzymes to bind with substrates, 
but bound substrates cannot be converted to products. Kinetically, this decreases 
Vmax with little effect on Km (Figure 6c). Uncompetitive inhibitors bind to the 
enzyme-substrate complexes and hinder the conversion of substrate to product 
(Figure 7c). Both apparent Vmax and Km will decrease because of the removal of 
activated enzyme-substrate complexes (Figure 6d). Mixed inhibition possesses 
more complicated kinetics, in which inhibitor binding affects both substrate 
binding and the function of the active site. Kinetically, both the apparent Vmax and 
Km are altered by inhibitor binding but, unlike the above three types of inhibitions, 
it does not possess a constant Km/Vmax value.  
Irreversible enzyme inhibitors usually covalently modify target enzymes 
and inhibit their activity. Inhibition cannot be removed by increasing substrate 
concentration or through dialysis. In Figure 8a, most irreversible inhibitors contain 
electrophilic reactive groups which react with nucleophilic amino acid side chains, 
such as hydroxyl, amine and thiol groups, inside or near enzyme active sites.43 
Example reactive groups include nitrogen mustards, aldehydes, haloalkanes, 
alkenes, phenyl sulfonates or fluorophosphonates.43 Some irreversible inhibitors 
are used as probes to study the mechanisms of enzyme catalysis.44 Irreversible 
inhibitors exhibit time-dependent inhibition and their potency cannot be 
characterized by IC50. Instead, irreversible inhibitors are evaluated using second 
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order rate constants for inactivation (Kobs /[I]),45-46 where Kobs is the pseudo-first 
order rate constant of inactivation (Figure 8b), and [I] is the inhibitor 
concentration.47 Irreversible enzyme inhibitors are widely used as antibiotics, 
such as penicillin. 
 
 
Figure 6. Enzyme inhibition kinetics of (a) uninhibited enzyme, (b) competitive 
inhibition, (c) noncompetitive inhibition and (d) uncompetitive inhibition (Figure 
copied from ref 41).   
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Figure 7. Mechanisms of (a) competitive inhibition, (b) noncompetitive inhibition 
and (c) uncompetitive inhibition (originally copied from ref 42). 
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Figure 8. (a) Irreversible inhibition of enzymes through covalent modification of 
amino acids residues inside or near the active site. (b) Time-dependent inhibition 
of an irreversible inhibitor. The slope of the inactivation curve is the pseudo-first 
order rate constant, Kobs.46 
Allosteric regulation controls enzyme or protein activity through the 
binding of an effector molecule at a protein's allosteric site, which is located at a 
site other than the active site (Figure 9).3 Generally, allosteric regulators are 
structurally different from substrate molecules, and can trigger conformational 
changes of whole proteins. Allosteric inhibitors can behave as competitive or 
noncompetitive inhibitors, kinetically.48 Molecules that target the allosteric sites of 
enzymes are promising drug candidates; possessing the advantages of high 
specificity, lower toxicity and cooperativity with other ligands.49-50  
11 
 
Figure 9. Allosteric regulation of (a) enzyme activation and (b) enzyme inhibition. 
Discovery of Enzyme Modulators 
Discovery of molecules that are able to control enzyme activity through 
noncovalent/covalent interactions is central to therapeutics51. Many drugs are 
enzyme inhibitors, or molecules capable of inhibiting or activating protein-protein 
interactions52, so their discovery and development is an active area of research 
in biochemistry and pharmacology. 
In early drug development, the only way to discover enzyme modulators 
is by trial and error. Combinatorial chemistry which is evolved from early organic 
chemistry research focused on strategies for generating molecular diversity 
becomes a powerful tool for developing and optimizing small-molecule 
modulators.53 Combinatorial chemistry generally involves the rapid synthesis of a 
large number of different, but structurally-related molecules that have been 
designed to have potential effects on target proteins. Diversity-oriented synthesis 
12 
has recently been developed to generate large libraries of small molecules with 
structural and functional diversity.54  
High-throughput screening (HTS) technologies have become more and 
more important in the rapid identification of active lead compounds from a large 
molecule library.55  HTS is defined as the process in which large batches of 
compounds are tested for binding activity or biological activity against target 
molecules. The test compounds can act as enzyme inhibitors or activators, 
ligands for binding, agonists or antagonists for receptor-mediated intracellular 
processes, etc. Several detection approaches are applied to the screening 
process, like absorbance, fluorescence, polarization56, dynamic light scattering57, 
surface plasma resonance58 and mass spectrometry.59-60 Today, most HTS 
processes are highly automated and robotic with screening levels as high as 
100,000 per day61. Many lead compounds selected from HTS are found to inhibit 
enzymes through aggregation-based mechanisms with poor specificity.62-64 
Developing new screening strategies to differentiate drug leads from 
aggregation-inducing compounds is a challenge for HTS technology. 
Recently, rational design of small molecules has been applied to 
discovering enzyme modulators utilizing the knowledge in three-dimensional 
protein structure and advances in computer simulation of protein-small molecule 
interactions (e.g. molecular docking and molecular mechanics).65-66 Novel 
strategies, like click chemistry, are used to design and select multi-valent enzyme 
inhibitors (Figure 10).67    
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Figure 10. Inhibitor discovery by click chemistry.67 
Peptides for Ligand Discovery 
Peptides represent a very promising class of potential protein-modulating 
molecules due to their large chemical diversity68 and the existence of well-
established methods for library synthesis69. Peptides and their derivatives are 
found to inhibit many important enzymes70, like dehydrogenases71, protein 
kinases72 and proteases.73 Cell-permeable peptides are becoming more and 
more useful in blocking cellular signaling pathways and drug delivery.74-75 There 
is a growing realization that, by using peptides as building blocks, it is possible to 
create synthetic structures with affinities and specificities comparable to natural 
antibodies76-77. It has also been shown that a peptide or small-molecule ligand 
that binds to a unique region of an enzyme can be used for orientation-specific 
enzyme immobilization on a solid support78-80 in order to optimize its activity and 
stability.  
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More and more drug discovery studies have shown that the chemical 
diversity of a molecular library is crucial for discovering potential lead compounds 
that affect target enzymes.53-54,81 Peptides possess huge sequence diversity as 
the size of peptide chemical space is defined by: Y = Xn, where Y is the total 
number of molecules in the space, X is the size of the set of unique amino acid 
substituents, and n is the number of residues in a peptide. For example, the 
entire space of a natural peptide library containing 10-mer peptides is 2010, or ~ 
1013. Considering that there are hundreds of unnatural amino acids that have 
been developed so far82-83, potential library sizes are actually even bigger. The 
magnitude of possible peptide sequence combinations is the basis of protein 
functional diversity. 
Several strategies have been developed to create large libraries of 
peptides. In Figure 11, phage display84-85 and mRNA display86 are two widely 
used in vitro selection methods for peptide ligand discovery, which harness 
molecular biology and peptide synthesis to generate peptide libraries with sizes 
from 106 to more than 1013. Purely chemical strategies for generating large 
peptide libraries are developed based on the one-bead one-compound (OBOC) 
approach or “split and mix”.87 In Figure 12, for OBOC approach, solid-phase 
supports (bead) are first separated into vials with a single amino acid coupled in 
each vial.  After the first coupling, the beads from different vials are mixed 
together in a random fashion, then separated and a second amino acid is 
coupled. A library size with more than 106 unique compounds will be generated 
after several rounds of “split and mix”. 
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Figure 11. Two popular in vitro selection methods of peptide ligand discovery. (a) 
Types of phage display85 and (b) mRNA display.86  
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Figure 12. Steps in peptide library synthesis based on OBOC strategy.87 
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Discovery of Ligands on Microarray 
Microarrays have been in use as high-throughput screening platforms to 
study molecule-molecule interactions with addressable patterns for each 
compound on an array surface since the 1990s (Figure 13).69 A typical 
microarray can contain a library of molecules from a few hundred up to more 
than one million on a chip area of several square centimeters, with picomoles of 
compound at each spot.88-91 Compared to selection library methods (e.g. mRNA 
and phage display), microarrays give out the information of each individuals in a 
given molecular library. 
 
 
Figure 13. A high-density microarray.  
High-density microarrays represent a powerful approach to screening for 
molecules that alter enzymatic functions92-94. Microarrays have been used for this 
purpose in the past, by constructing arrays of small molecules 95-97, peptides98-99 
and nucleic acids.100 A typical small-molecule array contains more than 10,000 
compounds synthesized on functionalized glass slides (25 mm × 75 mm ) with 
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features ranging from 50 – 300 μm in diameter.101  The most commonly-used 
approaches for immobilizing small molecules are shown in Figure 14, including 
epoxide-, isocyanate- and fluoroalkysilane-coated surfaces, and PNA (peptide 
nucleic acid) encoding small-molecule arrays.100,102 Small-molecule arrays have 
been used to discover inhibitors of enzymes103, like protein kinase C103, cysteine 
proteases102, metalloproteases104 and histone deacetylases.95, 105  
 
 
Figure 14. Representative approaches used to immobilize small molecules 
including (a) epoxide-coated surfaces, (b) isocyanate-coated surfaces, (c) 
fluoroalkylsilane-coated slides and (d)  PNA (peptide nucleic acid) encoding 
small-molecule arrays.101 
Peptide microarrays were first introduced by Stephen Fodor who 
synthesized of an array of 1024 peptides for binding to a monoclonal antibody.69 
There are three generally-used approaches for the preparation of peptide 
microarrays, printing of pre-synthesized peptides106, SPOT synthesis107 and light-
19 
directed, spatially-addressable synthesis.98 In Figure 15, several strategies for 
the immobilization of pre-synthesized peptides on glass slides are presented.108 
Commercial devices for printing molecules on activated surfaces are available, 
for instance, the Telechem Nanoprint System. SPOT- synthesis, which follows 
standard Fmoc chemistry, is another easy technique that permits the parallel 
synthesis of large numbers of addressable peptides on a cellulose membrane 
support, as shown in Figure 16.109-110 Light-directed in situ sythesis generally 
utilizes photolabile protecting groups, photo-generated acid111 and masks to 
selectively deprotect features on a microarray, and can generate a high-density 
microarray containing more than 100,000 peptides (Figure 17).98, 108  
In an effort to understand the enzymatic pathways and functions, 
substrate profiling of protein kinase, phosphatase and protease has been 
performed on peptide microarrays by printing or synthesizing peptide-based 
molecules on surfaces (Figure 18).99,112-115 More importantly, substrate specificity 
determination greatly aids the design of novel enzyme substrates and 
inhibitors.113 It is possible to identify new enzyme inhibitors and evaluate their 
IC50 values using peptide- or peptoid-arrays.90,116 In Figure 19, activity-based 
protein profiling (ABPP), which utilizes active-site-directed probes to profile the 
functional states of enzymes in proteomes, has also been performed on 
microarrays with improvements in sensitivity, resolution and enzyme identification 
as compared to the traditional liquid chromatography-mass spectrometry (LC-MS) 
method.114 Recently, a reactome array was developed to sense the metabolic 
phenotypes and networks for cell populations and communities.117 In Figure 20, 
the reactome array contains 1,676 dye-linked substrate molecules which are 
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designed to represent central metabolic pathways and detect enzymatic activity 
in the pathways.  
 
 
Figure 15. Methods for immobilizing pre-synthesized peptides on surfaces using 
(a) an amino group to aldehyde linker, (b) an aminooxyacetyl group to glyoxylyl 
linker, (c) a cysteine residue to thioester linker , (d) a cyclopentadiene residue to 
benzoquinone linker and (e) a cysteine residue to maleimide linker.108  
21 
 
Figure 16. Amino acid coupling cycle for SPOT-synthesis.110  
 
 
Figure 17. Light-directed, spatially-addressable peptide array synthesis.108 
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Figure 18. Mapping substrate specificity of protein tyrosine phosphatase on a 
phospho-peptide microarray.112 
 
 
Figure 19. Antibody-based ABPP microarrays where proteomes are labelled, in 
solution, with fluorescent-based probes and then captured on glass slides with 
enzyme-specific antibodies.114  
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Figure 20. Reactome array for sensing the links between the metabolome and 
genome.117 
In order to perform high-throughput enzyme activity screening, 
microwell118 and microdroplet arrays119-120 have been developed, which physically 
separate the array elements in such a way that the enzymatic reaction products 
remain localized at each feature and cannot diffuse between them. Another 
essential issue for screening catalytic reactions is maintaining enzyme activity on 
microarray surfaces. Hydrogels, which contain large quantities of solvent and 
behave as intermediates between dry and wet systems, are applied to 
peptide/protein arrays for this purpose.121 In Figure 21, a semi-wet 
peptide/protein array is produced using a supermolecular hydrogel composed of 
glycosylated acetate which provides a suitable semi-wet reaction medium.122 
New technologies are under development to improve the microarray platform for 
protein interaction and enzyme activity profiling, including self-assembling protein 
arrays123 and label-free enzyme arrays detected by mass spectrometry124 or 
surface plasmon resonance.125   
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a 
b 
 
Figure 21. A semi-wet peptide/protein array using supermolecular hydrogel. (a) 
Gel formation and (b) enzymatic assay in the hydrogel.122 
In this dissertation, a new method for identifying modulators of enzyme 
function is described that involves screening arrays of 10,000 defined and 
addressable peptides on a polymer-coated glass slides, for the ability to interact 
with enzymes and change their activity. In Chapter 2, I will discuss the coating of 
enzyme-bound microarrays with viscous poly vinyl alcohol (PVA) polymer, which 
allows the simultaneous monitoring of enzyme-peptide binding and peptide-
bound enzyme activity. In Chapter 3, I will describe the discovery of peptides that 
modulate enzyme function, identified from performing enzyme assays on PVA-
coated peptide arrays. In Chapter 4, an aggregation-based peptide inhibition 
mechanism is explored in detail. In Chapter 5, peptides selected from 
microarrays are used to modify surfaces for capturing enzymes with improved 
activity and stability. In Chapter 6, the commercialization of the above technology 
25 
will be discussed. Finally, in the last chapter, Chapter 7, I will discuss issues that 
have been faced during experimentation, and suggest some future improvements. 
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CHAPTER 2: POLYMER-COATED MICROARRAY FOR MEASURING 
CATALYTIC ACTIVITY 
ABSTRACT 
A method is developed for screening catalytic activity on high-density 
peptide arrays. A polyvinyl alcohol (PVA) solution was applied to array surfaces 
to limit the diffusion of product molecules released from enzymatic reactions, 
allowing the simultaneous measurement of enzyme activity and binding at each 
peptide spot. Further development of PVA coating involved the modification of 
PVA using anti-product antibodies to slow down diffusion of the product, and the 
design of cascade reactions in the polymer layer for detecting the enzymes 
without a profluor substrate. Part of this work was published on the Journal of 
American Chemical Society.  
INTRODUCTION 
Enzyme regulation plays an important role in biological metabolism1 and 
the ability to control enzyme activity through non-covalent interactions is central 
to therapeutics2. The modulation of enzymes is also important for industrial 
production of products and in enzyme-based assays.3-4 Screening libraries of 
small molecules, peptides and nucleic acids has been used to identify ligands 
that bind to proteins and modulate their function.5-6 Peptides are promising 
molecules for the modification of enzyme function because of the large chemical 
diversity available7 and established methods for library synthesis8. In principle, 
assaying high-density microarrays of molecular libraries provides a high-
throughput approach to screening for molecules that alter enzymatic function. 
Microarrays have been used for this purpose in the past9-10, by constructing 
arrays of small molecules5,11-12 or peptides13-14, printing the enzyme substrate on 
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the surface14-16 and activity-based protein profiling17. However, in general, the 
ability to measure enzyme activity on standard slide-based arrays is limited by 
diffusion of reaction products away from the sites of enzyme action. This problem 
is normally overcome by physically separating the array elements in such a way 
that enzymatic reaction products cannot diffuse between them, for example 
microwell18 and microdroplet arrays19-20. Hydrogel, which contains large 
quantities of solvent and behaves as an intermediate between dry and wet 
systems, can maintain the activity of biomolecules, or even cells immobilized on 
it21 , and has applications in many biological processes, such as protein22 or cell 
immobilization23, bioresponsive sensing24-25 and biomedical applications26-28. 
Recently, hydrogels have been applied to protein arrays for assaying enzyme 
activity29 and protein-ligand interactions30.   
A method for monitoring enzymatic reaction on the high-density 
microarray is described that involves screening an array of 10,000 defined and 
addressable peptides on a polymer-coated glass slide.31 The slow diffusion of 
product molecules in the polyvinyl acohol coating layer makes it possible to 
resolve the enzyme activity in the spots with little cross contamination.   
EXPERIMENTAL SECTION 
Chemicals Amplex®Red, Fluorescein di-β-D-galactopyranoside (FDG), 
resorufin β-D-galactopyranoside (RBG), fluorescein diphosphate (FDP) and 
Alexa Fluor 647 were purchased from Invitrogen (Eugene, OR). Phenylethyl β-D-
thiogalactoside (PETG), horseradish peroxidase (HRP), β-galactosidase (β-Gal, 
E.coli), alkaline phosphatase (APase), alcohol dehydrogenase, glucose 
dehydrogenase, poly vinyl alcohol (PVA, M.W.: 124,000~186,000), 4-nitrophenyl 
phosphate (PNPP), phenazine methosulfate (PMS), phosphate buffered saline 
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(PBS) and tris buffered saline (TBS) were obtained from Sigma (St. Louis, MO). 
Polyclonal anti-fluorescein antibody was purchased from Abcam (Cambridge, 
MA). A 4 mg/mL stock solution of β-Gal was prepared in 10 mM potassium 
phosphate buffer with 0.1 mM MgCl2 at pH 7.4. A 1.2 mg/mL stock solution of 
APase was prepared in 0.1 M Tris containing 50 mM NaCl, 10 mM MgCl2 and 0.1 
mM ZnCl2 at pH 8.2. 2.5 mg/mL HRP stock solution was prepared in pH 6, 10 
mM sodium acetate.  
Photobleaching experiment The diffusion coefficient of fluorescein was 
measured by Fluorescence Recovery after Photobleaching (FRAP). FRAP 
experiments were conducted on a Zeiss LSM 510 Meta confocal microscope 
(Jena, Germany) with a 40 ×, 1.3 NA oil-immersion objective using the 489 nm 
laser line. Fluorescence emission was collected using 515 nm LP and 505-550 
nm BP filters. The fluorescein concentration was 50 μM. FRAP experiments were 
carried out by first bleaching a circular region (Diameter, 34 μm) at high laser 
power setting (100 mW), then scanning the bleached region with low laser power 
setting (0.5 mW) to monitor the fluorescence recovery process. The laser power 
setting listed above is the input laser power to the microscope. The actual laser 
power at sample is much lower after passing through the lens system and the 
filters. The diffusion coefficient D can be determined from the τ1/2 (fluorescence 
recovery half-time) according to the following equation37,  
DrwD )4/( 2/1
2  ,                              (1) 
where w is the actual radius of the bleached region, τ1/2 corresponds to the time 
when the fluorescence intensity reaches 50% of complete recovery, rD=0.88 for 
circular beams. 
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Microarray fabrication Peptide microarrays were generated using the 
established, in-house printing method in the Center for Innovations in Medicine.32 
Each microarray was prepared by robotically spotting approximately 10,000 
distinct polypeptide sequences, in duplicate, on a glass slide possessing an 
amino-silane surface coating. Synthesized peptides (70% purity) were purchased 
from Alta Biosciences Ltd (Birmingham, UK). Each polypeptide was 20 residues 
in length and the 17 amino-terminal positions were randomly chosen from 19 
amino acids (excluding cysteine) using a pseudo-random computational process. 
The last three carboxy-terminal positions of each peptide constituted a glycine-
serine-cysteine (GSC) linker, used for conjugating the peptides to amino-silane 
surfaces through the C-terminal cysteine via a maleimide linker, Sulfo-SMCC 
(Pierce, Rockford, IL). A Telechem Nanoprint60 was used to spot approximately 
500 pL of 1 mg/mL peptide per feature on glass slides with 48 Telechem series 
SMP2 style 946 titanium pins.  
Enzyme assays on PVA-coated arrays As shown in Figure 22, a 
microarray containing 10,000 20-mer, random-sequence peptides was first 
incubated with a solution containing dye-labeled enzyme (AlexaTM 647), allowing 
the enzyme to bind with peptides on the array surface (Figure 22a). Unbound 
enzyme was washed off, and a substrate analogue (fluorescent-based) was 
mixed with a 5 % (%w/w) PVA buffer solution and spin-coated onto the array 
surface to form a ~ 50 μm layer (Figure 22b). The PVA-coated array was then 
incubated in a constant humidity chamber to allow the enzymatic reaction to 
occur. The substrate molecules in the PVA layer were converted to products by 
the enzymes bound to specific peptides on the array surface (Figure 22c), and 
remained localized at the peptide spot because of the PVA viscosity. For each of 
37 
the 10,000 peptides in the array, both the relative binding level of AlexaTM 647-
labeled enzyme and the relative amount of fluorescein produced during the 
incubation period were determined by dual color scanning (Figure 22d). Each 
array experiment was repeated at least three times under the same conditions for 
statistical analysis. HRP33, APase34 and β-Gal35 were chosen as representative 
enzymes due to the availability of substrate analogues (Amplex Red, FDG and 
FDP in Figure 22e) and the wealth of structural and mechanistic information 
available for these enzymes.  
Microarray data analysis Array images were first processed with 
GenePix Pro 6.0 (Molecular Devices, Sunnyvale, CA), and then microarray data 
was imported into GeneSpring 7.2 (Agilent, Foster, CA) for statistical analysis. To 
enable statistical comparisons between experiments, each slide was median-
normalized: the raw data was normalized to the median signal of each array. 
Because enzyme activity sometimes appeared artificially low at the edge of the 
array due to insufficient PVA coating, peptides in these regions were not selected 
as candidates for further analysis. 
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Figure 22. The overall process for screening peptide/enzyme interactions using 
peptide arrays. (a) Enzyme incubation. (b) PVA coating on the array surface. (c) 
The enzymatic reaction takes place in the PVA layer. (d) Fluorescent scanning 
images (a representative region) of binding (Alexa 647) and activity (fluorescein) 
for β-Gal on the PVA-coated array. Conditions: β-Gal, 5 nM; incubation time, 2 
hours at room temperature; substrate, 50 µM FDG; PVA concentration, 5%; 
reaction time, 3 mins at room temperature. (e) Substrate analogues Amplex Red, 
FDP and FDG used for evaluating activity of HRP, APase and β-Gal, respectively.    
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RESULTS AND DISCUSSION 
Limiting Diffusion using a Polyvinyl Alcohol Layer In general, the 
ability to measure enzyme activity on standard slide-based arrays is limited by 
diffusion of reaction products away from the sites of enzyme action. As shown in 
Figure 23a, serious cross-contamination between nearby spots was observed 
when incubating the enzyme bound array in buffer solution. In order to limit the 
diffusion of the products so that they remained in the immediate vicinity of the 
bound enzyme on the array (Figure 23b), the enzyme substrate was applied in a 
thin coating of Polyvinyl Alchohol (PVA).  
PVA is non-fluorescent, optically transparent, water soluble and highly 
viscous and has applications in many biological assays (Figure 24).36-37 The 
diffusion coefficient of fluorescein in a layer of 5% PVA in phosphate buffer was 
measured via fluorescence recovery after photobleaching (FRAP)38 and found to 
be ~ 50 μm2/s, roughly 6-fold slower than in phosphate buffer without PVA 
(Figure 25). As shown in Figure 22d, it was relatively easy to resolve the enzyme 
activity in the spots with little cross contamination.  This is because of the 
spacing of the spots, the viscosity chosen for the PVA and the time allow for 
reaction.  In addition, each peptide is duplicated side-by-side producing a 
distinctive oval around the active spot.  
Enzyme activity on PVA-coated microarrays In Figure 26, the ability of 
enzymes to function in the PVA medium was demonstrated by real-time imaging 
of bound β-Gal activity on PVA-coated peptide arrays. One can see that the 
fluorescent products continued to accumulate over the entire time of the 
measurement, indicating that the enzyme remained active during that period. 
This assay was also used to determine the best period of time to run the enzyme 
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reactions for subsequent analyses.  The greatest resolution between spots was 
observed after the first few minutes of incubation at the substrate concentrations 
used here. 
In general, cross contamination is only an issue for peptides that bind the 
enzyme very weakly and those peptides are normally of little interest. In the 
typical strong enzyme-binding spot analyzed in Figure 27 a and b, the product 
molecule diffused ~160 μm (in one direction) away from the original spot and 
resulted in 10% of the signal intensity from one spot at the neighboring spot.  The 
average distance between two spots is ~ 100 μm (from edge to edge). This only 
represents a significant problem when a spot showing very weak activity resides 
next to one with very strong activity (Figure 27c and d). Less cross contamination 
can be obtained by either increasing the space between spots or using more 
viscous PVA. To eliminate ‘false positives’ as much as possible, the candidates 
were selected from the top 200 strong binders. 
 
 
Figure 23. Product diffusion on the microarray surfaces coated with (a) 
phosphate buffer solution and (b) 5% polyvinyl alcohol. β-Gal was bound to the 
array surface for catalyzing the hydrolysis of FDG to fluorescein.  
41 
 
Figure 24. Structure of PVA, PVA solid and viscous solution. 
 
  a b   0.1 s t = 0 
 
Figure 25. FRAP of fluorescein in 5% PVA. (a) A series of images of the 
fluorescence recovery process using 50 μM fluorescein. Photobleaching started 
at t = 0 s, duration of the laser bleaching, ~ 50 ms; scanning interval,  ~ 100 ms. 
(b) Data analysis of the fluorescence recovery process. 2/1 = 1.3 s.   
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Figure 26. The ability of enzymes to function in PVA polymer. (a) Real-time 
imaging of β-Gal activity on PVA-coated peptide arrays. Fluorescence is 
generated due to the production of resorufin released from RBG hydrolysis. A 10 
mm × 20 mm region of the slide containing ~ 1000 spotted peptides was 
monitored (only a very small part of that area is shown). Conditions: substrate, 10 
µM RBG; PVA concentration, 5%; Scanning interval, 1 min. (b) Kinetics 
measurements of RBG hydrolysis catalyzed by bound β-Gal on peptide arrays. 
Each trace represents the kinetics at a particular spot (a particular attachment 
peptide) on the array.  
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Figure 27. Diffusion of fluorescent products between spots in the PVA layer. 
Single-line scanning analysis of (a) enzyme binding intensity and (b) bound 
enzyme activity was used to evaluate how diffusion affects the measurements of 
specific activity on the surface. The amount of product that has diffused between 
spots can be determined by comparing the peak width of enzyme activity (which 
is subject to diffusion) to the peak width of enzyme binding (no diffusion). (c) and 
(d) are example spots that contaminate each other. 
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Ultra-slow product diffusion in an antibody-modified PVA layer In the 
above discussion, the diffusion contamination between spots was reduced to a 
low level if the reaction was incubated for a few minutes. However the diffusion of 
product molecules will still become more serious with increasing reaction time, 
even in a PVA layer. It complicates the application of the technology to slow 
catalytic reactions. To overcome this problem, anti-product antibodies were used 
to capture product molecules in the PVA medium and slow down their diffusion 
rate (Figure 28). Antibodies are big molecules of ~ 150 kDa, diffusing much more 
slowly than small molecules. If the product molecules released from an 
enzymatic reaction are captured by antibodies, the product-antibody complex will 
exhibit a much slower diffusion rate compared to free product molecules in the 
PVA layer due to the larger molecular size. To test the concept, an FITC-labeled 
antibody was applied in the 5% PVA layer to mimic the diffusion properties of a 
flurorescein-bound antibody (Figure 29). The diffusion coefficient of FITC-labeled 
antibody was measured to be ~ 2.8 μm2 /s in 5 % PVA, which was much slower 
than the fluorescein diffusion rate of ~ 50 μm2 /s in the same PVA medium.  
An anti-fluorescein antibody was added to the PVA layer to capture the 
fluroescein molecules released from the β-Gal enzymatic reaction on the array 
surface.  As shown in Figure 28b and c, the fluorescein molecules were restricted 
to the vicinity of the enzyme-bound spots catalyzing them by adding the 
antibodies in the PVA layer, while the molecules diffused further away from the 
reaction sites and contaminated nearby spots in the blank PVA layer. Figure 30 
shows that the enzyme-bound spots were resolved better for the arrays coated 
with antibody-modified PVA compared to the array coated with blank PVA.  
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Figure 28. Ultra-slow product diffusion in PVA by (a) adding anti-product 
antibodies which will capture product molecules and form big complex diffuse 
slowly in PVA medium. Fluorescent images of (b) the long-period fluorescein 
diffusion in blank 5% PVA and (c) the fluorescein diffusion in 5% PVA mixed with 
500 nM anti-fluorescein antibody. β-Gal catalyzed the conversion of fluorescein 
from FDG and the reaction on array was incubated for 30 minutes with 500 nM 
FDG in the PVA layer.  
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Figure 29. FRAP of FITC-labeled antibody in 5% PVA. Photobleaching started at 
t = 3 s; duration of the laser bleaching, ~ 100 ms; scanning interval,  ~ 400 ms;  
Antibody concentration, 2 μM; 2/1 = 23 s; D=2.8 μm2/s. 
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Figure 30 Diffusion of fluorescent products between spots in the PVA layers with 
or without antibody. Single-line scanning analysis of the arrays coated with (a) 
blank 5% PVA; (b) 5 % PVA mixed with 200 nM anti-fluorescein antibody and (c) 
5% PVA mixed with 500 nM anti-fluorescein antibody.  
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Design of a cascade reaction in a PVA layer to measure 
dehydrogenase activity The methods discussed above use a profluor as a 
substrate for the enzymes assayed. This limits the application of the technology 
because many enzymes do not have fluorescent substrate analogues available. 
To solve this difficulty, approaches were developed to use a nonfluorescent 
product to generate a fluorescent signal with designed enzyme-linked cascade 
reaction in the PVA coated array. In the enzyme-linked cascade reaction, the 
nonfluorescent product of the enzyme under study acts as a substrate for a 
second enzyme/catalyst in the PVA layer and thereby is converted to 
fluorescence signal for monitoring.  To explore this concept, dehydrogenases 
were chosen as the target enzymes to study. These enzymes oxidize a substrate 
by transferring one or more hydrides (H−) to an acceptor, usually NAD+/NADP+. 
Dehydrogenases represent a class of important enzymes that are prevalent in 
biological metabolism. Some of these enzymes are drug targets or are used as 
catalysts for chemical syntheses in biocatalysis industry. 
The reaction product NAD(P)H has weak fluorescence at 460 nm with 
maximal excitation absorbance at 340 nm, which is not appropriate for standard 
microarray fluorescent imaging. A cascade reaction was designed to use 
NAD(P)H as the substrate to convert nonfluorescent resazurin to strongly-
fluorescent resorufin  (emission ~ 585 nm), catalyzing by phenazine methosulfate 
(PMS) in Figure 31. Alcohol dehydrogenase (ADH, Yeast; ~ 141 kDa, tetrameric 
protein) and glucose dehydrogenase (GDH, Thermoplasma acidophilum; ~ 155 
kDa, tetrameric protein) were used as model enzymes in this study due to the 
wealth of structural and mechanistic information available for these enzyme 
systems. In Figure 32, an enzyme-bound peptide array was coated with a PVA 
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layer containing ethanol, NAD+, PMS and resazurin, which allowed the cascade 
process of first converting NAD+ to NADH by surface-bound dehydrogenase, and 
then generating strongly fluorescent resorufin by the PMS-catalyzed reduction of 
resazurin. The activities of dehydrogenase bound to the microarray were 
monitored using regular fluorescence imaging and the activity of enzyme-bound 
spots could be resolved. The fluorescent molecules diffused farther away from 
the original spot for the cascade reaction than for the single-substrate reaction, 
due to the two diffusion steps of NADH and resorufin involved in the cascade 
reaction. A further optimization may be achieved by conjugating NAD+ to PVA 
polymer (120 ~ 180 kDa) to slow down the diffusion of the molecules.     
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Figure 31. A cascade reaction that uses NAD(P)H genreated by dehydrogenase 
to convert nonfluorescent resazurin to fluorescent resorufin. Phenazine 
methosulfate (PMS) was used to catalyze the cascade reaction.  
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Figure 32. Monitoring of dehydrogenase activity on peptide microarrays through 
a designed cascade reaction in the PVA layer. Conditions: 10 nM Alexa647-
labled ADH first bound to peptide array for 2 hours at room temperature in pH7.3 
buffer containing 1 X PBS and Tween 20 (0.05%(%v/v)); PVA coating: 5% (%w/w) 
PVA containing 3% (%v/v) ethanol concentration, 1 mM NAD+; 50 μM PMS and 
100 μM resazurin;   reaction time, 3 mins at room temperature. 
CONCLUSION 
The approach described above represents a surprisingly simple and 
general method of screening enzyme activity on high-density microarrays. The 
peptide slides can be printed inexpensively and rapidly analyzed given an 
appropriate enzyme assay. PVA were simply prepared with various reaction 
buffers and coated onto the array surface to limit the diffusion of product 
molecules. As a result, many enzyme/peptide pairs can be processed in parallel 
under almost any set of desirable conditions. Much slower diffusion of product 
molecules on the microarray surface was achieved by modifying PVA with anti-
product antibodies, allowing longer periods for monitoring the catalytic reaction 
and accumulating product. The further development of enzyme-linked cascade 
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reaction in the PVA layer made it possible to detect enzymes without using a 
profluor as substrate. As a demonstration, the activity of a peptide-bound 
dehydrogenase was measured on the microarray surface. Finally, this approach 
is not limited to peptides; any small molecule that is arrayable could also be 
searched in this format for enzyme modulators.   
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SUPPLEMENTARY INFORMATION 
 Detailed Protocol of Enzyme assay on the PVA coated arrays β-Gal 
was labeled with Alexa Fluor 647 (Invitrogen) and diluted to 5 nM in bovine 
serum albumin (BSA) buffer (1× PBS with 3% (v/v) BSA and 0.05% Tween 20). 
The activity of the labeled β-Gal was ~ 75% of that of the wild type in solution. 
The peptide array was first prewashed with surface cleaning solvent (7.33% (v/v) 
acetonitrile, 37% isopropyl alcohol and 0.55% trifluoroacetic acid in water) for 5 
minutes to reduce non-covalent bonding peptides on the array surface. The array 
was then treated to block any active SMCC (Sulfosuccinimidyl-4-(N-
maleimidomethyl)cyclohexane-1-carboxylate) linker remaining from peptide 
spotting by applying 330 μL capping buffer (3% (v/v) BSA, 0.02% (v/v) 
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mercaptohexanol, 0.05% (v/v) Tween20 in 1×PBS) and incubating for one hour in 
a humidity chamber (Stain Tray Slide System, Fisher Scientific, Pittsburgh, PA). 
The array was then washed once with pH 7.4 TBST (1 × Tris-Buffered Saline and 
0.05% (v/v) Tween 20) and at least twice with water, and dried by centrifuging at 
1,500 rpm for 5 minutes. After the blocking step, 330 μL 5 nM Alexa 647-labeled 
β-Gal was applied to the array. The array with the enzyme solution was sealed 
using an AbGene Frame (Fisher Scientific) and slide cover, and incubated for 
two hours at room temperature in a humidity chamber in the dark as shown in 
Figure 22a. After two hours, the slide cover was removed and the array was 
washed three times with 1 × TBST, 5 minutes each wash. This was followed by 
three washes with pH 7.4 10 mM potassium phosphate and 100 μM MgCl2 buffer, 
5 minutes each wash. 
The array was then spin-coated with a 5% PVA solution that included 
substrate analogues FDG or RBG, forming a thin PVA layer on the array surface 
(Figure 22b) using a commercial spin coater (WS-400B-6NPP/LITE, Laurell, 
North Wales, PA). The PVA solution was prepared by adding PVA powder into 
phosphate buffer and then heating the solution in a microwave. The heating 
process was repeated several times until all of the PVA powder was dissolved. 
The enzyme substrate (or substrate analogue) was then added into the PVA 
solution to the desired substrate concentration. About 700 μL of PVA solution 
was added onto the array surface and the array was fist spun at 300 rpm for 10 
seconds, and then spun at 2,000 rpm for 15 seconds to make the polymer 
spread evenly on the array surface. The final PVA layer thickness was ~50 μm 
as measured by scanning confocal microscopy (DNAscope™ , Biomedical 
Photometrics Inc., Waterloo, Canada). 
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The PVA-coated peptide array was immediately incubated in a humidity 
chamber allowing the enzyme reaction to take place. The substrate molecules in 
the PVA layer were converted to fluorescent product by the enzyme molecules 
bound to specific peptides in the array. The product molecules diffused slowly in 
the viscous PVA polymer layer and remained near the spot where the reaction 
took place. The reaction incubation time was optimized by using a real-time 
scanning fluorescence imager and observing the accumulation of product 
molecule during the reaction (Figure 26). In this work, the incubation time for 
enzyme reaction was 3 mins for β-Gal , HRP and APase. The slides were then 
dried rapidly in a vacuum desiccator to stop the enzymatic reaction. The array 
was then read by a standard array reader (PerkinElmer, Waltham, MA) with dual 
color scanning using 488 and 647 nm laser lines. The AbGene frame and Open 
Frame DNAscope™ were used for real time imaging of the β-Gal activity on the 
array surface. Each array experiment was repeated at least three times under the 
same conditions for statistical analysis.  
The array activity assays for APase and HRP used procedures very 
similar to that used for β-Gal.  In the case of APase, FDP was used as the 
substrate analogue and a Tris buffer (1×Tris-Buffered Saline) was used instead 
of a phosphate buffer. The array activity assay for HRP was performed by using 
50 μM Amplex®Red and 1 mM H2O2 as substrates mixed with 5% PVA prepared 
in 10 mM, pH 6 sodium acetate.  The Amplex®Red was converted to resorufin 
(emission at ~585nm) by HRP in the presence of H2O2. 
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CHAPTER 3: EXPLORING PEPTIDE SPACE FOR ENZYME MODULATORS 
ABSTRACT 
A method is presented for screening high-density arrays to discover 
peptides that bind and modulate enzyme activity. Simultaneous measurement of 
enzyme activity and binding at each peptide spot were performed on the 
polyvinyl alcohol-coated array. For proof of concept, it was possible to identify 
peptides that bound to horseradish peroxidase, alkaline phosphatase and β-
galactosidase and substantially altered enzyme activity by comparing the binding 
level of peptide to enzyme and bound enzyme activity. This basic technique can 
be used to screen many enzymes in parallel under many set of desirable 
conditions, and may be generally applicable to find peptides or other small 
molecules that modify enzyme activity. The work has been published on the 
Journal of American Chemical Society.  
INTRODUCTION 
Enzyme modulation is crucial for living systems and plays important roles 
in regulating metabolic function.1 Searching for small-molecule ligands with the 
ability to control enzyme activity is central to therapeutics2. The modulation of 
enzymes is also of great interest to industrial production of products and in 
enzyme-based assays.3-4 Screening libraries of small molecules, peptides and 
nucleic acids has been used to identify ligands that bind to proteins and modulate 
their function.5-6 Peptides are promising molecules for the modification of enzyme 
function because of the large chemical diversity available7 and established 
methods for library synthesis8. In principle, assaying high-density microarrays of 
molecular libraries provides a high-throughput approach to screening for 
molecules that alter enzymatic function. Microarrays have been used for this 
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purpose in the past9-10, by constructing arrays of small molecules 5,11-12 or 
peptides13-14, printing the enzyme substrate on the surface14-16 and activity-based 
protein profiling17. The recent development of polymer-coated microarrays makes 
it possible to simultaneous screen enzyme activity and binding on high-density 
array surfaces and identifies peptide modulators that bind to the enzyme with 
substantial alteration of its function.18   
In this chapter, a method for identifying modulators of enzyme function is 
described that involves screening an array of 10,000 defined and addressable 
peptides on a polymer-coated glass slide for the ability to interact with an enzyme 
and change its activity. This is performed by simultaneously monitoring both the 
binding and activity of the enzyme at each peptide spot on the microarray 
surface.  
EXPERIMENTAL SECTION 
Chemicals and Microarray data analysis have been described in 
Chapter 2. 
Solution-based enzyme assays Peptides selected from microarrays 
were synthesized and purified for use in solution-based enzyme assays, which 
were performed on a SpectraMax M5 96 well plate reader (Molecular Device, 
Sunnyvale, CA). Peptides were first incubated with enzyme for half an hour, and 
then the substrate was added to the wells to measure the enzyme activity. At 
least three replicates were tested parallel. The IC50 of each inhibitor was 
determined by fitting the concentration vs. inhibition curve to the function ‘Fit 
LogIC50’ in the GraphPad program using the fitting equation “Y=Bottom+(Top-
Bottom)/(1+10^(X-LogIC50))”. The “Bottom” term was constrained to 1, which 
represents the maximal inhibition of 100%. The “Top” term was constrained to 0, 
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which represents the minimal inhibition of 0%. Each data point is the average of 
at least 3 replicates.  
RESULTS AND DISCUSSION 
In Chapter 2, a method of monitoring enzymatic reactions on high-density 
peptide microarrays was developed, which involved the coating of the array 
surface with a viscous PVA polymer. This allowed the simultaneous 
measurement of enzyme activity and binding at each peptide spot, and made it 
possible to identify peptides that bind to the enzyme and substantially modulate 
its activity. Three enzymes were tested on the peptide microarray in Figure 33: 
HRP, APase and β-Gal which were monomeric, dimeric and tetrameic proteins, 
respectively.  
The binding level and activity of HRP on the peptide array for the 1000 
top binders are shown in Figure 33a. As expected, the total activity generally 
increases with the amount of enzyme bound. Peptides exhibiting weak binding 
and lower enzyme activities are mainly distributed in Region (i) (lower left). 
Peptides that show both strong binding and enzyme activities are distributed in 
Region (ii) (upper right). The peptides that appear to bind and inhibit enzyme 
activity are distributed in Region (iii), showing relatively weak enzyme activity 
compared to the level of enzyme binding. The surface-specific activity of HRP 
was calculated for each of the spots, in Figure 33a, by dividing the total bound 
enzyme activity by the total binding intensity (Figure 33d). The median-
normalized specific activities ranged from 0.33 to 11, suggesting that the nature 
of the interactions between the enzyme and the peptides on the surface was 
affecting enzyme activity. Higher than median activities for particular peptides 
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could be due to favorable orientation of the enzyme by the peptide or peptide 
stabilization of a more active conformation (Figure 34a).   
 
Figure 33. The median-normalized activity of bound (a) HRP, (b) APase and (c) 
β-Gal on the microarrays as a function of the amount of enzyme bound to a 
particular peptide on the array for the 1000 strongest binding peptides. 
Frequency distribution of surface specific activity of (d) HRP, (e) APase and (f) β-
Gal. Examples of raw fluorescence images associated with specific classes of 
peptides in the array are shown as an inset of (c). (i) Weak enzyme activity with 
weak enzyme binding intensity, (ii) strong enzyme activity with strong enzyme 
binding intensity, (iii) weak enzyme activity with strong enzyme binding intensity.  
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Figure 34. The predicted inhibition of monomeric, dimeric and tetrameric 
enzymes on a peptide microarray surface. (a) For monomeric enzymes (e.g. 
HRP), the inhibition on the microarray may be due to direct active-site interaction 
or an inhibitory orientation with poor substrate accessibility. (b) For dimeric 
enzymes with two structural independent subunits (e.g. APase), one subunit of 
the two interacts with peptides and is inhibited, leaving the other subunit still 
active. (c) For tetrameric enzyme, one would expect to see partial inhibition on 
the array surface since there will be one or two subunits that do not bind to 
peptides and are open to substrates.  Complete inhibition of enzyme will be 
observed only if the peptide can trigger a conformational change of the whole 
tetramer enzyme via induced allosteric inhibition.   
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Figure 33b shows the binding level and activity of APase on the peptide 
array for the 1000 top binders. As shown, the increase of total activity with the 
amount of enzyme bound forms a significantly tighter correlation compared to 
HRP, with the median-normalized specific activity ranging from 0.42 to 6.6 
(Figure 33e). APase (E.coli) is a homo-dimeric enzyme which possesses an 
unshared active site in each subunit19 (structure independent). Therefore, it may 
be that only one of the two subunits interacts with a surface peptide at any given 
time and, thus, only the activity of that subunit is modulated (Figure 34b). This 
idea is consistent with the fact that the lowest activities were about half of the 
median surface-specific activities of the enzyme. The seven peptides with the 
lowest surface-specific activities were selected, re-synthesized and tested in 
solution. Four of them were able to inhibit the enzyme in solution as well as on 
the surface, with IC50 values (concentration of 50% inhibition) between 400 µM 
and 900 µM (Figure 35).  
In contrast to APase, β-Gal (E.coli) is a tetramer with the active site on 
the interface of two subunits and has known allosteric inhibition and activation20-21. 
As shown in Figure 33c, there is much more variation in β-Gal surface specific 
activity than APase activity as a function of binding to different peptides. 
Examples of the raw fluorescence images associated with each region of the 
activity vs. binding plot are shown in the right panel of Figure 33c. Strong 
inhibition was seen in Region (iii) with the median-normalized specific activity 
lower than 0.2. If the peptides were acting as simple active site inhibitors, one 
might expect that β-Gal would never have less than about one half to three 
fourths of the median activity of the enzyme due to its tetrameric nature and the 
likely ability of peptides on the surface to interact with only one or two subunits at 
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a time. However, the strong inhibition in Region(iii) of Figure 33c suggests that 
some peptides may trigger conformational changes in the entire tetramer and 
inhibit the whole enzyme (Figure 34c). Consistent with this scenario, activities as 
low as 0.07 of the median surface specific activity are observed (Figure 33f).  
These results suggest that the simple ratio assay described here may provide a 
general approach for directly detecting peptides that allostericly inhibit particular 
enzymes.   
10 peptides inhibiting β-Gal (in Region (iii) of Figure 33c) and resulting in 
low surface-specific activities on the array were synthesized and purified for 
solution-based enzyme inhibition assays. 8 Peptides (1-8) were found to inhibit β-
Gal activity in solution with a range of IC50 values from 1.2 μM to 30 μM (Table 1 
and Figure 36). As controls, several peptides from Region (ii) of Figure 33c 
(strong binding and high activity, e.g. peptide 11) and from Region (i) (weak 
binding and weak activity, e.g. peptides 12 and 13) were also synthesized and 
tested for the inhibition of β-Gal in solution. These peptides showed much higher 
IC50 values (> 300 μM) than the selected peptide inhibitors. These results imply 
that modulation of enzyme activity via surface-bound peptides corresponds, in 
most of cases, to the effects of those peptides in solution. As an indication of the 
specificity of the selected peptide inhibitors, they were also tested for their effects 
on APase activity. Most showed much weaker inhibition of APase than β-Gal 
(>20 fold higher IC50).  
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Figure 35. Solution test of selected peptides inhibiting alkaline phosphatase 
activity. Peptides 1-7 are the inhibitors selected that have the lowest surface 
specific activity (normalized to the median of the array). The IC50 of the peptide 
inhibition is measured at a substrate concentration of 200 µM PNPP and an 
alkaline phosphatase concentration of 200 µg/L; Temperature, 25 oC.  All data is 
the average of at least 3 replicates. Inhibition percentage = (Activity uninhibited – 
Activity inhibited) / Activity uninhibited.  
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Table 1. Solution test of selected peptides inhibiting β-Gal activity *. 
 
* Peptides 1-10 are selected inhibitors, Peptides 11-13 are the negative control 
peptides and 14 is the competitive inhibitor of β-Gal. The IC50 of the peptide 
inhibition is measured at 25 oC with a substrate concentration of 100 µM RBG 
(resorufin β-D-galactopyranoside) and a β-Gal concentration of 150 µg/L. APase 
concentration, 200 ug/L, PNPP (4-nitrophenyl phosphate) 200 μM. ‘-’ unavailable 
data due to poor solubility or weak inhibition. 
In addition to inhibitors, peptides that enhanced the surface-specific 
activities of β-Gal were also found (e.g. Region (ii) in Figure 33c) which suggests 
that peptides can stabilize the active conformations of each enzyme (or 
alternatively optimize its orientation and function on a surface). In room-
temperature solution tests, some peptides in that region enhanced β-Gal activity 
by about 50% but did not show better activation of β-Gal in solution than negative 
control peptides (weak binder peptide 12 and 13), possibly because β-Gal is 
stable and nearly at its maximum possible activity in solution at room 
temperature. However, this result suggests that it might be possible to discover 
peptides that enhance stability of the enzyme on the surface or under other 
conditions that might favor inactive conformations of the enzyme (e.g. high 
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temperature, pH). To test this, the enzymes were bound to peptides on 
microarrays at room temperature and then the arrays were incubated at higher 
temperatures (61° C for APase and 55 ° C for β-Gal, both enzymes lose activity 
at the high temperatures, Figure 37) for one hour and assayed for activity at 
room temperature (HRP was not tested in this way). As shown in Figure 38, most 
of the peptide-bound enzymes lose activity after incubation at high temperature 
(compared to Figure 33). However, there are a few peptide-bound enzymes that 
remain stable after this treatment (Table 2 and 3).  For Apase, up to a 14-fold 
improvement in remaining activity over the median level is observed after 
extended exposure to a temperature of 61 °C and for β-Gal up to 31-fold 
improvement in remaining activity over the median after exposure to 55 °C is 
observed.  These results suggest that both enzymes can be stabilized by binding 
to particular peptides.  
CONCLUSION 
In this chapter, the PVA-coated microarray was demonstrated to discover 
modulators of enzyme activity by performing parallel measurements of activity 
and binding for the entire array. HRP, APase and β-Gal tested in this work 
demonstrated a wide variation in binding to the 10,000 spotted peptides (median-
normalized binding levels from 0.2 to 70 for HRP, from 0.1 to 150 for APase and 
from 0.3 to 85 for β-Gal).  A >10-fold variation over the array was found in the 
surface specific activity for HRP and APase and >100-fold for β-Gal. In most 
cases tested, enzyme inhibition observed on the surface was also demonstrated 
in solution-based measurements. Not only was it possible to rapidly and easily 
discover enzyme inhibitors in this fashion, enzyme stabilizing peptides were also 
found; some of the peptides were able to promote maintenance of enzyme 
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activity on the surface even after prolonged exposure to high temperatures. Such 
peptides might be useful in enzyme immobilization applications, resulting in 
improved enzyme activity and stability.  
Why can peptides have such diversities in modulating enzyme function? 
In solution, proteins are quickly switched between different conformations, some 
conformation may favorite catalytic reactions, and some may induce inhibition. It 
is possible that a peptide prefers to bind to a specific conformation of the enzyme, 
and thereby switch the balance between different protein conformations. This can 
either make the protein more stable, or damage its activity. It will be very 
interesting if peptides can be used to differentiate the conformations of the target 
proteins.  
The PVA-coated peptide slides can be rapidly analyzed given an 
appropriate enzyme assay and assayed at many conditions (like temperature, pH 
and solvent).  It may be a generally method to discover molecules that modulate 
enzyme activity at desired conditions. 
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Figure 36. Curve fit determining the IC50 of peptides inhibiting β-Gal using the 
data presented in Table 1. GraphPad Prism 5 was used for enzyme kinetics 
fitting to the equation: Y=Bottom + (Top-Bottom)/(1+10^(X-LogIC50)). Here, 
Bottom is constrained to 1 which represents the maximal inhibition of 100% and 
Top is constrained to 0 which represents the minimal inhibition of 0%.  All data is 
the average of at least 3 replicates. Inhibition percentage = (Activity uninhibited – 
Activity inhibited) / Activity uninhibited. 
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Figure 37. Solution thermal stability of (a) β-Gal (E.Coli) and (b) APase (bovine). 
The native enzyme (not bound to a peptide) is first incubated at the test 
temperature for one hour, and then the activity is determined by adding substrate. 
In the thermal stability graph, β-Gal loses most of its activity at temperatures 
higher than 55 °C and Apase loses activity at temperatures higher than 60°C. 
The activities at different temperatures are normalized to the value of highest 
activity and all values are the average of three replicates.   
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Figure 38.  Thermal-stability test of APase and β-Gal on a peptide microarray. (a) 
APase was first bound to a peptide microarray at room temperature, and then 
incubated in Tris buffer at 61 °C for one hour. The activity was measured by 
coating the APase bound slides with 50 µM FDP and incubating for 3 minutes at 
room temperature. (b) β-Gal was first bound to microarray at room temperature, 
and then incubated in phosphate buffer at 55 °C for one hour. The activity was 
measured by coating the β-Gal bound slides with 50 µM FDG and incubating for 
3 minutes at room temperature. The selected regions (circled) contain peptides 
binding to the enzyme with the highest specific activity after incubating at high 
temperature.  
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Table 2 Selected peptides for enhancing thermalstability of APase *. 
 
* APase was first bound to a peptide microarray at room temperature, then 
incubated in Tris buffer at 61 °C for one hour. The activity was measured by 
coating the APase bound slides with 50 µM FDP and incubating for 3 minutes at 
room temperature. All data is median normalized and the average of at least 
three parallel slides. 
 
Table 3 Selected peptides for enhancing thermalstability of β-Gal *. 
 
* β-Gal was first bound to the microarray at room temperature, and then 
incubated in phosphate buffer at 55 °C for one hour. The activity was measured 
by coating the β-Gal bound slides with 50 µM FDG and incubating for 3 minutes 
at room temperature. All data is median normalized and the average of at least 
three parallel slides. 
 
 
72 
REFERENCES 
(1) Gordon, G. H.; Wu, C. W. Science 1971, 172, 1205-1211. 
(2) Drews, J. Science 2000, 287, 1960-1964. 
(3) Sheldon, R. A. Adv. Synth. Catal. 2007, 349, 1289-1307. 
(4) Palomo, J. M. Curr. Org. Synth. 2009, 6, 1-14. 
(5) Vegas, A. J.; Fuller, J. H.; Koehler, A. N. Chem. Soc. Rev. 2008, 37,  
            1385-1394. 
(6) Schreiber, S. L. Chem. Eng. News 2003, 81, 51-61. 
(7) Devlin, J.; Panganiban, L.; Devlin, P. Science 1990, 249, 404-406. 
(8)  Fodor, S.; Read, J.; Pirrung, M.; Stryer, L.; Lu, A.; Solas, D. Science 
            1991, 251, 767-773. 
(9) Sun, H.; Chattopadhaya, S.; Wang, J.; Yao, S. Q. Anal. Bioanal. Chem. 
            2006, 386, 416-426. 
(10) Dı´az-Mocho´n, J. J.; Tourniaire, G.; Bradley, M. Chem. Soc. Rev. 2007, 
            36, 449-457. 
(11) Vegas, A. J.; Bradner, J. E.; Tang, W.; McPherson, O. M.; Greenberg, 
E. F.; Koehler, A. N.; Schreiber, S. L. Angew. Chem. Int. Ed. 2007, 46, 
            7960-7964. 
(12) MacBeath, G.; Koehler, A. N.; Schreiber, S. L. J. Am. Chem. Soc. 1999, 
            121, 7967-7968. 
(13) Northen, T. R.; Greving, M. P.; Woodbury, N. W. Adv. Mater. 2008, 20, 
            4691-4697. 
(14) Houseman, B. T.; Huh, J. H.; Kron, S. J.; Mrksich, M. Nat. Biotechnol. 
            2002, 20, 270-274. 
(15) Kohn, M.; Gutierrez-Rodriguez, M.; Jonkheijm, P.; Wetzel, S.; Wacker, R.; 
Schroeder, H.; Prinz, H.; Niemeyer, C.; Breinbauer, R.; Szedlacsek, S.; 
            Waldmann, H. Angew. Chem. Int. Ed. 2007, 46, 7700-7703. 
(16)     Salisbury, C. M.; Maly, D. J.; Ellman, J. A. J. Am. Chem. Soc. 2002, 124, 
            14868-14870. 
(17) Sieber, S. A.; Mondala, T. S.; Head, S. R.; Cravatt, B. F. J. Am. Chem. 
            Soc. 2004, 126, 15640-15641. 
(18)  Fu, J.; Cai, K.; Johnston, S. A.; Woodbury, N. W. J. Am. Chem. Soc.  
73 
            2010, 132, 6419-6424. 
(19) Boulanger, R. R.; Kantrowitz, E. R. J. Biol. Chem. 2003, 278, 23497- 
            23501. 
(20) Accolla, R. S.; Cina, R.; Montesoro, E.; Celada, F. P. Natl. Acad. Sci. 
            USA 1981, 78, 2478-2482. 
(21) Jacobson, R. H.; Zhang, X. J.; DuBose, R. F.; Matthews, B. W. Nature 
            1994, 369, 761-766. 
74 
CHAPTER 4: ENZYME INHIBITORS SELECTED FROM PEPTIDE 
MICROARRAYS 
ABSTRACT 
In this chapter, peptides screened from high-density microarrays were 
evaluated for their ability to inhibit β-galactosidase in solution. Peptide inhibitors 
acted through a noncompetitive inhibition mechanism which was sensitive to 
enzyme and detergent concentrations. Dynamic light-scattering showed that the 
aggregation of enzymes with peptides was involved in the inhibition of enzyme 
activity. Detailed sequence analysis of peptides revealed that positive residues, 
such as K and R, played a critical role in peptides inhibiting enzymes. Further, it 
was possible to select additional peptides which either enhanced the inhibitory 
activity of these peptides or neutralized it. It may start with an enzyme in an 
inhibited form in solution and turn it on via a secondary peptide interaction.  
INTRODUCTION 
Small molecule-modulators that regulate enzyme activity play an 
important role in many biological functions, and are crucial for drug discovery.1-2 
Screening libraries of small molecules, peptides and nucleic acids has been 
widely used to discover ligands that bind to proteins and modulate their 
functions.3-4 Peptides represent a promising class of potential enzyme 
modulators5 due to their large chemical diversity6 and the existence of well-
established methods for library synthesis7. Peptides and their derivatives are 
found to inhibit many important enzymes8, like dehydrogenases9, protein 
kinases10 and proteases.11 Cell-permeable peptides are becoming more and 
more useful in blocking cellular signaling pathways.12-13 High-density microarrays 
containing peptide libraries or enzyme substrates synthesized or printed directly 
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on array surfaces, provide a high-throughput approach to screening for peptides 
that alter enzymatic function.14-16 Recently, hydrogel-coated microarrays have 
been used as a means of screening for enzyme activity modulated by specific 
protein-peptide interactions, which has made it possible to perform activity 
assays using high density microarrays.17   
It is important to understand the unique mechanisms of peptide-
modulated enzyme inhibition in order to explore potential applications of peptide-
based molecules to therapeutics and the biocatalysis industry. In this chapter, 
peptides screened from microarrays were evaluated for their ability to inhibit β-
galactosidase (β-Gal) which revealed the aggregation of peptide-inhibited 
enzyme complexes. Previously, many lead compounds selected from high-
throughput screening inhibit enzymes noncompetitively with poor specificity and 
act by aggregating them into colloidal particles.18-20 As what will be described 
below, it is possible to find peptides that specifically aggregate or dissociate with 
the enzyme only in the presence of another particular peptide. It may switch the 
enzyme between an aggregated, inhibited state and an active state by using two 
or more selected peptides.  
EXPERIMENTAL SECTION 
Chemicals. Fluorescein di-β-D-galactopyranoside (FDG), resorufin β-D-
galactopyranoside (RBG) and Alexa Fluor 647 (Alexa 647) were purchased from 
Invitrogen (Eugene, OR). Phenylethyl β-D-thiogalactoside (PETG), β-
galactosidase (β-Gal), poly vinyl alcohol (PVA, M.W.: 124,000~186,000), 
phosphate buffered saline (PBS) and tris buffered saline (TBS) were obtained 
from Sigma (St. Louis, MO). A 4 mg/mL stock solution of β-Gal was prepared in 
10 mM potassium phosphate buffer with 0.1 mM MgCl2 at pH 7.4. A 2 mg/mL 
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stock solution of peptide was first prepared in pure water, and then diluted in 
phosphate buffer to the desired concentration. 
Microarrays. Microarray production and associated assay protocols were 
described in previously chapters. GenePix Pro 6.0 (Molecular Devices, 
Sunnyvale, CA) and GeneSpring 7.2 (Agilent, Foster, CA) were used for 
microarray data analysis, also described previously.17,21 To enable statistical 
comparisons between experiments, each slide was median-normalized: the raw 
fluorescence intensities from each peptide spot were normalized to the median 
fluorescence signal for each array.  
Solution-based enzyme assays. Solution-based enzyme assays were 
performed on SpectraMax M5 96 well plate readers (Molecular Device, 
Sunnyvale, CA) as described previously.17 Briefly, peptides were first incubated 
with enzyme for 20 minutes, and then the substrate was added into the wells to 
measure the enzyme activity, including at least three replicates per peptide. The 
IC50 of each inhibitor was determined by fitting the concentration vs. inhibition 
curve to the function ‘Fit LogIC50’ as defined in the program GraphPad using the 
fitting equation “Y=Bottom+(Top-Bottom)/(1+10^(X-LogIC50))”. The “Bottom” 
term was constrained to 1, which represents the maximal inhibition of 100%. The 
“Top” term was constrained to 0, which represents the minimal inhibition of 0%. 
The inhibition percentage of peptide-inhibited enzyme was calculated using the 
equation of “Inhibition Percentage = (Activity uninhibited – Activity inhibited)/ Activity 
uninhibited × 100%”. Km and Vmax (and thus kcat, when combined with the total 
enzyme concentration used) of β-Gal were determined by fitting the activity vs. 
substrate concentration curves in the GraphPad program using the fitting 
equation of “Y=Vmax*X/(Km+X)”.  
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Dynamic Light Scattering (DLS). A Zetasizer Nano S (Malvern 
Instruments) was used for the DLS study. The stock peptide and enzyme 
samples were first passed through 0.2 μm filters to remove any dust particles. 1X 
TBS with 0.1 mM MgCl2 was filtered using a 0.2 μm filter and used as the buffer 
in the DLS experiments. The peptide and enzyme samples were diluted down to 
desired concentration using filtered buffer.   
Fluorescence Correlation Spectroscopy (FCS). FCS measurements 
were conducted using a confocal microscope (ECLIPSE TE2000-U, Nikon) with 
continuous wave laser excitation at 532 nm (Millennia Xs, Spectra-Physics). The 
fluorescence was collected after passing through a filter designed for the 
fluorescent dye, Alexa 555 (emission ~ 580 nm), and then split into two parts with 
equal intensity and directed to two avalanche photodiodes, as described 
previously22. Correlation curves were measured using a dual-channel digital 
correlator with a sample time of 12.5 ns (Flex2k-12x2, Correlator, Bridgewater, 
NJ) and the vendor’s software. The analysis was performed using home-written 
software based on LabView (version 7.1, National Instruments). For all 
measurements, the dye-labeled β-Gal concentrations were in the low nanomolar 
range.  
RESULTS AND DISCUSSION 
In the previous chapters, an approach was described for screening high-
density arrays to identify peptides that bind to enzymes and modulate their 
activity.17 In Table 4, 7 peptides, selected from microarrays, were found to inhibit 
β-Gal activity in solution with IC50 values ranging from 1.0 μM to 13 μM. 
Substrate titration studies suggested that most peptides are noncompetitive 
inhibitors (except peptide 1), generating more reduction in Kcat with less change 
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on Km (Figure 39).  As controls, the Michaelis constants for PETG-inhibited β-Gal 
(a known competitive inhibitor)23 were also measured, which showed that the 
competitive inhibition of β-Gal generated a reduction in Km with little effect on Kcat 
compared to uninhibited enzyme, as expected. The peptides were also tested for 
their effects on APase activity as an indication of the specificity of the peptide 
inhibitions. Most showed much weaker inhibition of APase than β-Gal (>20 fold 
higher IC50).  
 
Table 4 β-Gal inhibitory peptides selected from microarraysa. 
 
a 1-7 are selected peptide inhibitors, 8 is a known competitive inhibitor of β-Gal. 
The IC50 of peptide inhibition was measured at 25 °C with a substrate 
concentration of 100 μM RBG (resorufin  β-D-galactopyranoside) and a β-Gal 
concentration of 150 μg/L. *Km and Kcat  are measured at a peptide concentration 
approximately equal to the IC50.  
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Figure 39. Curve fit used to determine the apparent Km and kcat values for β-Gal 
inhibited with various peptides in this study; the resulting values are given in 
Table 4. GraphPad Prism 5 was used for enzyme kinetics fitting to the equation: 
Y=Vmax*X / (Km+X). The enzyme concentration was 150 μg/L (~ 0.33 nM); the 
RBG substrate was titrated from 10 μM to 240 μM. All data is the average of at 
least 3 replicates. 
Titration studies of enzyme and detergent concentration were performed 
to further explore the inhibition of β-Gal by peptides. In Figure 40a, each of the 
peptides inhibiting β-Gal showed a ~2-fold or greater decrease in inhibition with 
increasing enzyme concentration between 1 and 1000 nM enzyme. Given that 
the peptide concentration was held at 20 µM, the strong dependence on enzyme 
concentration for inhibition suggests that the stoichiometric ratio of peptides to 
enzyme is quite high for effective inhibition of β-Gal (apparently on the order of 
100 in most cases). In Figure 40b, peptide inhibition also shows sensitivity to the 
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detergent concentration, with the inhibition of β-Gal becoming weaker with 
increasing detergent, at constant peptide concentration. The degree of this effect 
was rather variable from one peptide to another (e.g., very small effect on 
peptide 1, but a dramatic effect on peptide 2), but in all cases some affect on the 
ability of the peptide to inhibit was observed.  In contrast, the enzyme and 
detergent concentrations had little effect on the competitive inhibition of β-Gal 
using PETG. These results are consistent with peptide induced aggregation of 
the enzyme as a mechanism of inhibition.  This generally requires a high inhibitor 
to enzyme ratio and is sensitive to detergents that disrupt aggregation.18     
Dynamic light scattering (DLS) was used to further explore the role of 
aggregation in the inhibition mechanism of the peptides. Three peptides 
(peptides 1-3) were tested using DLS because these peptides exhibited good 
solubility and strong inhibition. As shown in Figure 41a, DLS of 30 µM peptide 1 
alone showed a major peak with a hydrodynamic diameter of 3 ~ 6 nm, which 
corresponds to the size of the 20-mer linear peptide. β-Gal in solution at 50 nM 
showed a peak at ~ 15 nm, which is consistent with the diameter of the enzyme. 
When peptide 1 and β-Gal were mixed at the same final concentrations, enzyme 
activity was strongly inhibited (inhibition percentage > 90%), and large particles 
with diameters > 200 nm were observed by DLS. Apparently, multiple Peptide 1 
molecules associate with the enzyme, creating large aggregates. This inhibition 
only occurs when both the peptide and the enzyme are present. A similar effect 
was also observed for peptide 2 (Figure 41b), which aggregated with β-Gal and 
inhibited enzyme activity.  For peptide 3, DLS showed that peptide 3 aggregated 
at inhibitory concentrations even in the absence of the enzyme (Figure 41c). 
Presumably inhibition in the case of peptide 3 occurs via an interaction between 
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the peptide aggregates and the enzyme, as has been observed in previous 
studies.18, 24  
Dynamic light scattering gave clear evidence for aggregation and for two 
different modes of aggregation-associated inhibition (enzyme induced 
aggregation or interaction between the enzyme and pre-existing peptide 
aggregates). However, because of the concentration limitations of that technique, 
it was necessary to take data at rather high enzyme concentrations (> 50 nM).  
Fluorescence correlation spectroscopy (FCS) was used to study the aggregation 
of peptide with β-Gal at low nanomolar enzyme concentrations. Figure 42a 
shows the autocorrelation curves derived from monitoring the fluctuations in dye 
molecules moving in and out of a small volume of liquid defined by the confocal 
optical system used to take these measurements.22 Small molecules like free 
Alexa 555 dyes move in and out of the volume rapidly and thus their 
autocorrelation decays completely within 2 ms (there resident time in the small 
volume was less than 2 ms). In contrast, the Alexa 555-labeled β-Gal (3 nM 
enzyme) gave rise to an autocorrelation trace that extended out to roughly 100 
ms, which was consistent with its much larger size. When 20 µM peptide 1 was 
added to the enzyme solution, causing the strong inhibition of β-Gal, the 
correlation time increased dramatically (it is difficult to measure, but was on the 
order of 60 s), indicating the formation of very large particles with long resident 
times in the confocal volume. This is shown dramatically in Figure 42b, right 
panel, where one can see large, long-lived fluctuations in the fluorescence from 
the confocal volume as a function of time, representing the slow movement of 
large particles in and out of the volume.  The dye molecules and labeled 
enzymes themselves do not show this behavior. Clearly, even at nanomolar 
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enzyme concentrations, the peptide is inducing aggregation under conditions that 
give rise to inhibition.   
 
 
 
Figure 40. Titration of enzyme and detergent concentrations with respect to 
peptide inhibition. (a) Peptide inhibition as a function of β-gal concentration 
ranging from 1 to 1000 nM. The peptides are ~ 20 μM, and PETG is ~ 50 µM. 
Enzyme activity is assayed using 50 μM FDG. (b) Peptide inhibition as a function 
of detergent concentration (Tween 20). PETG is used as a control as it inhibits β-
gal competitively. β-gal concentration:  ~ 1 nM. Inhibition Percentage = (Activity 
uninhibited – Activity inhibited)/ Activity uninhibited × 100%. 
83 
 
Figure 41. Dynamic light scattering studies of peptides inhibiting β-Gal. (a) The 
particle distributions of 30 µM peptide 1, 50 nM  β-Gal and the mixture of peptide 
1 with the enzyme were labeled with red, green and blue color, respectively. (b) 
The particle distributions of 150 µM peptide 2, 50 nM  β-Gal and the mixture of 
peptide 2 with the enzyme were labeled with red, green and blue color, 
respectively. (c) The particle distributions of 100 µM peptide 3 solution. For all the 
mixtures of peptides with enzymes, β-Gal was inhibited by more than 90%. 
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Figure 42. Fluorescence correlation study of β-Gal/peptide aggregation. (a) 
Fluorescence correlation decay of (i) Free Alexa 555 (Blue line), (ii) β-Gal (Red 
line) and (iii) β-Gal/peptide 1 complexes (Black line). (b) Time-dependent signals 
from monitoring fluorescence fluctuations in the confocal volume  of a 
microscope set up for single molecule detection (i) Free Alexa 555, (ii) β-Gal and 
(iii) β-Gal/peptide 1 complexes. Alexa 555, 10 nM; β-gal, 3 nM; peptide 1, 20 µM. 
Inhibtion Percentage, > 90%.  
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Alanine scanning and truncations of peptides 1 and 2 were used to 
examine the dependence of peptide inhibition upon the specific peptide 
sequences in solution. For peptide 1, an alanine scan showed that the positively-
charged residues at positions 4 (K), 5 (R), 8 (R) and 14 (R) played important 
roles in inhibiting β-Gal activity (Figure 43a(i)). Substitutions of those residues 
with alanine decreased the ability of the peptide to inhibit the enzyme by 5-10 
fold. It had been also observed that some substitutions made the peptide inhibit 
the enzyme stronger, for example, alanine substitutions at positions of 2 (V), 9(W) 
and 12 (V). The truncation analysis of peptide 1 revealed that a 12-mer 
positively-charged peptide, RVFKRYKRWGSC (pI 11.4), was able to inhibit the 
enzyme with nearly the same IC50 as the 20-mer peptide 1, as shown in Figure 
43b (i). This 12-mer peptide can be further reduced to a 10-mer peptide, 
FKRYKRWGSC (pI 10.2), with an IC50 of ~ 3 μM, which also maintains the ability 
to inhibit β-Gal. More comprehensive point-variant screening25-26 was applied to 
the shorter peptide, FKRYKERWGSC, to study the specific residue contributions 
to inhibition of β-Gal. In Figure 44, 49 single-point variants, containing all 
substitutions of the amino acid set { S, Y, E, L, W, Q, and R } in each of the 7 
randomized positions (FKRYKER – the GSC C-terminal linker was held constant 
for all peptides and the W residue was not altered), were synthesized, and tested 
for inhibition of β-Gal in solution. The results revealed that the FKRYKERWGSC 
sequence was nearly optimized; any amino acid substitution, except the 
replacement of R with K at position 5, resulted in decreasing the inhibition of β-
Gal. 
 In Figure 43a (ii), similar effects were observed for peptide 2 in that 
positively-charged lysine residues at positions 10 (K) and 16 (K) were most 
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important for inhibiting β-Gal activity. The enhancement of peptide inhibition was 
also observed for the alanine substitution at the position of 5 (F) with ~ 2-fold 
stronger inhibition of the enzyme. For the peptide, a 12-mer positively-charged 
peptide, KKQGYYYKLGSC (pI 9.7), was the critical fragment for inhibiting β-Gal. 
Clearly positively-charged residues have a great deal to do with the ability to 
inhibit.   
Stronger inhibition of β-Gal was observed by covalently crosslinking the 
inhibitory peptides with enzymes.  As shown in Figure 45, 20 μM PEP 1 was 
incubated with 30 nM β-Gal for 20 minutes first, then 0.5% formaldehyde was 
added to the peptide/enzyme mixture and incubated for another 20 mins inorder 
to crosslink the peptide with enzyme. The whole mixture was diluted by 100-fold 
in buffer in such a way that the free peptide concentration will be as low as 20 nM. 
For the uncrosslinked peptide/enzyme mixture, the enzyme activity was 
recovered to ~ 70% activity of the uninhibited enzyme solution. However, for the 
crosslinked peptide/enzyme mixture, it was still strongly inhibited with the activity 
was as low as ~ 6% of the uninhibited enzyme solution even though the peptide 
concentration was much lower than its IC50 (50-fold lower). The effect of 
formaldehyde crosslinking on enzyme activity was also studied as a control 
showing that enzyme still maintained ~50% activity. It suggested β-Gal was 
almost irreversible inhibited by crosslinking the inhibitory peptides with enzyme.  
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Figure 43. Alanine scans and sequential truncation measurements of peptide 1 
and 2 inhibitory activity. (a) An alanine scan of peptide 1 (i) and peptide 2 (ii) with 
respect to inhibition of β-Gal.  (b) A truncation scan of peptide 1 (i) and peptide 2 
with respect to inhibition of β-Gal. All inhibitions of alanine-substituted peptides 
were normalized to that of peptide 1 and peptide 2, respectively.  
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Figure 44. Point-variant screening of the peptide FKRYKRWGSC at each of the 
7 N-terminal positions including substitutions of residues {S, Y, E, L, W, Q, and 
R}. The inhibition of β-Gal by variants was normalized to that of the lead peptide, 
FKRYKRWGSC. 
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Figure 45. Enhancement of peptide-inhibiting β-Gal by corsslinking the inhibitory 
peptide with enzyme using 0.5 % formaldehyde. Final enzyme conc.: 0.3 nM; 
PEP 1 conc.: 20 nM. 50 μM RBG was used for assaying enzyme activity. 
Multiple peptides were observed that bound to the aggregated and 
inhibited β-Gal complex. In Figure 46, PEP1/ β-Gal  complex were applied to the 
peptide microarrays, several peptides showed higher signal intensity for binding 
to aggregated β-Gal complex than β-Gal free solution. Four peptides were 
selected that bound to the PEP1/ β-Gal complex and resulted in at least a 30-fold 
increase in enzyme inhibition relative to the PEP 1/enzyme complex alone (Table 
5, NEW 1 - 4). Solution tests showed that two of the selected peptides, NEW 3 
and NEW 4, enhanced the inhibition of PEP1/β-Gal complex by a factor of ~ 3 
when added to the solution, as shown in Figure 47. The other two peptides also 
enhanced the inhibition, but not as strongly. 
In contrast to inhibition reinforcement, two negatively-charged peptides, 
NEG 1 (EFSNPTAQVFPDFWMSDGSC, pI 3.4) and NEG 2 
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(ESVPTDLPMDTMEGKNWGSC, pI 3.9), were found to recover the activity of 
PEP1/ β-Gal complex. In Figure 48a, the activity of PEP1/β-Gal complex was 
measured as a function of NEG 1 concentration. The activity of inhibited enzyme 
was increased from less than 10% of the uninhibited enzyme to nearly 40 % by 
adding NEG 1, with a dynamic range of nearly 9-fold at most. A similar result was 
also observed for NEG 2-triggered recovery of inhibited β-Gal activity. Because 
the positive residues of PEP1 contributed greatly to the inhibition of β-Gal (Figure 
43 and 44), it is likely that these negatively charged peptides bind to the 
aggregates and destabilize the PEP 1/β-Gal complexes. The recovery 
percentage of the inhibited enzyme was related to initial PEP 1 concentration; the 
higher the PEP1 concentration, the lower the recovery percentage. It may be that 
either PEP1 can partially induce the permanent inhibition of β-Gal, or there are 
some very stable aggregated peptide/enzyme complexes, or perhaps partly 
inhibited core complexes, that cannot be completely destabilize by the 
negatively-charged peptides.  
 
Table 5 Four selected peptides that showed increased binding to the PEP 1/ β-
Gal mixture, as screened using peptide microarrays.  
 
a The microarrays were incubated with 5 nM Alexa 647-labeled β-Gal.  
b The peptide microarrays were incubated with a solution containing 5 nM Alexa 
647-labeled β-Gal and 10 µM PEP 1.   
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Figure 46. Peptides binding to the aggregated PEP1/β-Gal complexes found 
through screening on peptide microarrays. (a) Fluorescent scanning images (a 
representative region) of enzyme binding for 5 nM β-Gal (left) and the PEP1/β-
Gal mixture (right), respectively. β-Gal was labeled with Alexa 647.  Conditions: 
β-Gal, 5 nM; PEP1, 10 µM; incubation time, 2 h at room temperature. (b) The 
peptides that show increased binding to the enzyme when incubated with the β-
Gal and PEP1 mixture.   
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Figure 47. Peptides that inhibit β-Gal cooperatively with peptide 1. (a) NEW 1; (b) 
NEW 2; (c) NEW 3 and (d) NEW 4. β-Gal was first incubated with peptides for 20 
mins and then activity was assayed using 100 µM RBG at 25 ºC. 
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Figure 48. Activity recovery of inhibited PEP1/β-Gal complex using peptides (a) 
NEG 1 and (b) NEG 2. All enzyme activities are normalized to that of uninhibited 
enzyme. For the recovery tests, β-Gal was first incubated with peptide 1 for 20 
minutes, then the negatively-charged peptides (NEG 1 and NEG 2) were added 
into the mixture and incubated for another 20 minutes before enzyme activity was 
tested. Enzyme activity was assayed using 100 µM RBG.  
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There are some further considerations about the mechanism of peptide 
inhibiting enzyme. First, what is the possible kinetics process for peptide-inducing 
β-Gal aggregation and inhibition? As we know, enzymes are quickly switching 
between different conformations in solution. In Figure 49, enzymes prefer more 
to the active conformation with less aggregation in physiological conditions. But 
the inhibitory peptides may bind more tightly to the inactive conformation of the 
enzyme, and switch the balance more to the right. As a result, more and more 
enzymes bind to peptides with their inactive and sticky conformation, and finally 
most of the enzymes are inhibited and aggregated.  
 
 
Figure 49. Kinetics model of peptide-inducing β-Gal aggregation and inhibition.  
Another question is why we have not seen the classically competitive 
inhibitors of β-Gal for the peptides selected from microarray? As we discussed in 
Chapter 3, β-Gal is a tetrameric enzyme. If there was a peptide binding to the 
active site of β-Gal, it would only inhibit one subunit, and the enzyme can still 
maintain ¾ of the uninhibited activity. The inhibition is not significant on the 
microarray and difficult to be selected. As we predicted in Chapter 3, the strong 
inhibition of β-Gal observed on microarray cannot be caused by the active-site 
inhibition, it should be resulted from some nonclassical inhibitions, like 
noncompeptive inhibition, in such a way that the entire enzyme inhibition can be 
induced by peptide binding to one or two subunits of the tetramer.  
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How can we improve the assay methods to select classically competitive 
inhibitors? One method is to utilize the known competitive inhibitors of target 
enzymes to block the binding between peptides with enzymes on the microarray. 
As shown in Figure 50, peptides that bind to the target enzyme are identified by 
incubating the enzyme solution with peptide arrays. Then the similar assay is run 
again with the competitive inhibitor-bound enzyme solution. The peptides that 
specially bind to the active site of the enzyme may be blocked by the competitive 
inhibitor and thereby show the decrease in binding to the enzyme.  
 
Figure 50. Identification of peptides that bind to the active site of the target 
enzyme by blocking the peptide-enzyme interactions with known active-site 
binding inhibitor.  
In Figure 51, some peptides binding with dehydrofolate reductase (DHFR) 
were blocked by methotrexate (MTX) which is a competitive inhibitor of DHFR. 
This initial test shown that some peptides did bind to the region close to the 
active site and thereby the bindings were affected by the active-site binding 
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competitive inhibitors. The selection will be more efficient if the ligand blocking 
experiment is combined with the enzyme activity screening together. 
 
Figure 51. Methotrexate (MTX) blocking the binding of peptides with DHFR. 
Peptide binding with DHFR is shown in the left figure, and the blocking test with 
MTX is shown in the right figure.   
 
CONCLUSION 
In summary, a unique aggregation-mediated mechanism for inhibiting β-
Gal using peptides selected from microarrays has been demonstrated. 
Aggregated complexes were formed even at low nanomolar enzyme 
concentrations. Further study revealed that positively-charged peptide residues 
played important roles in inhibiting enzyme activity.  Stronger and irreversible 
inhibition of enzyme activity was observed by crosslinking the peptides with β-Gal. 
Moreover, multiple peptides were found to further regulate the activity of inhibited 
peptide/ β-Gal complex, either stabilizing the aggregated complex and resulting 
in stronger inhibition or destabilizing the aggregated complex and thereby 
Peptide binding with 100 nM 
Alexa555-labeled DHFR 
Peptide binding with 100 nM 
DHFR + 1 µM MTX  
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restoring the enzyme activity.  It should be possible to design switchable enzyme 
systems in this way, using pairs of selected peptides.  
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CHAPTER 5: PEPTIDE-MODIFIED SURFACES FOR ENZYME 
IMMOBILIZATION 
ABSTRACT 
A method is presented for utilizing peptide ligands to immobilize enzymes 
on surfaces with improved enzyme activity and stability. Ligands, selected from 
peptide microarrays and optimized through point-variant screening, were 
covalently attached to surfaces for the purpose of capturing target enzymes. 
Compared to conventional methods, enzymes immobilized on peptide-modified 
surfaces exhibited higher specific activity and stability, which might be generally 
applicable to immobilizing enzymes with optimized orientation, location and 
performance.  
INTRODUCTION 
Surface-immobilized enzymes play an important role in many biocatalytic 
processes and industrial applications.1-2 The activity, stability and selectivity of 
enzymes can be improved if they are immobilized properly on surfaces.1,3 Many 
conventional protein immobilization methods1, which rely on nonspecific 
absorption of proteins to solid supports or chemical coupling of reactive groups 
within proteins, have inherent difficulties, such as protein denaturation, poor 
stability due to nonspecific absorption4-5 and the inability to control protein 
orientation1,5. New strategies for enzyme immobilization are needed which allow 
precise control over orientation and position and thereby provide optimized 
activity. Peptides represent a promising class of potential protein-
anchoring/modulating molecules due to their large chemical diversity6 and the 
existence of well-established methods for library synthesis7. Peptide or small 
molecule ligands that bind to a unique region of a protein can be used for 
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orienting the protein and modulating its activity through specific ligand-protein 
interactions on a solid support.8-10 In this chapter, I will present a method for 
creating peptide-modified surfaces that immobilize a target enzyme with 
optimized orientation and activity.  
EXPERIMENTAL SECTION 
Chemicals Resorufin β-D-galactopyranoside (RBG) and Alexa Fluor 647 
were purchased from Invitrogen (Eugene, OR). β-galactosidase (β-Gal, E.coli), 
polyvinyl alcohol (PVA, M.W.: 124,000~186,000), 4-nitrophenyl phosphate 
(PNPP), Phosphate Buffered Saline (PBS) and Tris Buffered Saline (TBS) were 
obtained from Sigma (St. Louis, MO). BS³ (Bis[sulfosuccinimidyl] suberate) , 
alkaline phosphatase-conjugated strepavidin and iodoacetyl resin were 
purchased from Pierce (Rockford, IL). Sulfo succinimidyl-4-(N-maleimidomethyl) 
cyclohexane-1-carboxylate (Sulfo-SMCC) was purchased from bioWORLD 
(Dublin, OH). Aminated microwell plates were ordered from Corning. A 4 mg/mL 
stock solution of β-Gal was prepared in 10 mM potassium phosphate buffer with 
0.1 mM MgCl2 at pH 7.4.  
Enzyme immobilization on modified microwells Peptides were 
conjugated to aminated microwell surfaces through the specific reaction between 
C-terminal cysteines and the maleimide-activated surfaces, as shown in Figure 
52. 10 mM SMCC was prepared in 1X PBS buffer, pH 7.4. Next, 30 µL of SMCC 
was added into each aminated microwell and incubated for one hour at room 
temperature. The microwell plate was then briefly washed with pure water three 
times. Then, 30 µL of a 300 µM peptide solution, prepared in 1X PBS pH 7.4 plus 
1 mM TCEP, was thn added to the appropriate SMCC-activated microwells. The 
reaction was incubated for 4 hours at room temperature, in the dark. After the 
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conjugation reaction was complete, the microwells were washed for 5 minutes in 
1X TBST, three times, followed by three washes in water. To immobilize the 
enzyme on peptide-modified surfaces, 30 µL of 25 nM biotin-labeled β-Gal was 
incubated in the peptide-modified microwells for two hours in 10 mM phosphate 
buffer, pH 7.3 with 100 µM MgCl2 and 0.05% Tween 20 (v/v%), at room 
temperature. The microwells were washed for 5 minutes in 1X TBST, three times, 
followed by three washes in phosphate buffer. At this point, the β-Gal-bound 
microwells were ready for testing. β-Gal was labeled with biotin using EZ-Link 
Sulfo-NHS-Biotinylation Kit purchased from Pierce (labeling ratio: ~ two biotin per 
enzyme molecule). Figures 53-55 show the detailed optimization procedures for 
peptide-modified surfaces.  
Covalent attachment of β-Gal to NHS (N-Hydroxysuccinimide)-activated 
surfaces was performed using BS3 homogeneous amine-reactive cross-linker, as 
recommended by the manufacturer. First, 30 µL of 2 mg/mL BS3 prepared in 1X 
PBS, pH 7.4 was incubated with the aminated microwells for half an hour. Then, 
the microwells were briefly washed with nanopure water, three times, to remove 
unreacted BS3 molecules. Finally, 30 µL of biotin-labeled β-Gal was incubated 
with the microwells for one hour, which were then washed three times in 1 X 
TBST, followed by three washes in phosphate buffer.   
The activity assay of surface-bound β-Gal was performed on a 
SpectraMax M5 96-well plate reader (Molecular Device, Sunnyvale, CA) by 
adding 100 µL of 100 µM RBG into the wells. The relative amount of surface-
bound β-Gal was measured using an enzyme linked immunosorbant assay 
(ELISA). β-Gal was first labeled with biotin. Alkaline phosphatase-conjugated 
strepavidin (0.4 mg/ml) was diluted at 1:1000 in 1X PBS, 0.05% (v/v) Tween 20. 
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Next, 30 µL of streptavidin solution was added to the β-Gal-bound wells and 
incubated for one hour at room temperature. The streptavidin solution was then 
removed and the plate was washed three times with TBST buffer and three times 
with TBS buffer. Then, 200 µL of 1 mM PNPP was added to each well. The 
alkaline phosphatase activity was subsequently measured by reading the 
absorbance increase at 405 nm on the M5 plate reader. The β-Gal binding level 
was determined from the activity of alkaline phosphatase-conjugated strepavidin 
bound to the wells. 
 
 
Figure 52. The overall process for conjugating peptides to aminated microwells 
through specific reactions between C-terminal cysteines and maleimide-activated 
surfaces. 
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Figure 53. Optimization of SMCC conjugation: (a) raw fluorescence images of 
Alexa-647-labeled aminated microwells with SMCC capping at different 
concentrations. SMCC will conjugate to the amine groups on the microwells and 
prevent the labeling of Alexa-647 dye molecules. The higher the conjugation 
yield, the less the fluorescence from the labeled fluorophores; (b) Fluorescence 
intensities of Alexa-647-labeled microwells with different concentrations of SMCC 
capping; (c) surface conjugation yields of SMCC at different concentrations. The 
result shows that a 10 mM SMCC solution can be used to achieve a surface 
conjugation yield of more than 90%. 
105 
 
10 mM SMCC   Aminated  microwell 
  1200 µM 600 µM 300 µM 150 µM 75 µM 37.5 µM 
a 
0 300 600 900 1200 1500
0
10000
20000
30000
40000
Peptide Conc. (µM)
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 (a
. u
.)
b 
 
Figure 54. Optimization of peptide concentration for surface conjugation: (a) raw 
fluorescence images of Alexa-647-labeled microwells conjugated with different 
concentrations of peptide solution. 10 mM SMCC was first used to activate the 
aminated microwells, and then peptides were conjugated to SMCC-activated 
surfaces through specific reactions between the C-terminal cysteine and 
maleimide. Surface peptide densities were measured by labeling the microwells 
with amine-reactive Alexa 647. The more peptide on surface, the stronger the 
labeled fluorescence intensity due to the reaction between the dye and the 
peptide amine groups. (b) Surface fluorescence intensity as a function of peptide 
concentration used for conjugation. The peptide used is YHNN with a sequence 
of “YHNNPGFRVMQQNKLHHGSC”. 
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Figure 55. Optimization of peptide density for capturing β-Gal on peptide-
modified microwells. Different densities of surface-immobilized peptide were 
created by varying the concentrations of peptide solution used for immobilization. 
The amount of immobilized β-Gal started to get saturation when surface was 
modified with 300 µM or higher concentrations of peptide solution. The peptide 
used for optimization was YHNN.   
Determining Michaelis constants of immobilized β-Gal The 
determination of the enzyme kinetic constants (KM and kcat) of immobilized β-Gal 
was performed on peptide-modified iodoacetyl polyacrylamide resin (UltraLink, 
Pierce, 50-80 µm diameter). To modify the bead surface with peptide, peptide 
solutions were incubated with iodoacetyl resin for one hour in 50 mM Tris buffer, 
5 mM EDTA, pH 8.5.  The unreacted iodacetyl groups were then capped with 50 
mM L-cysteine. The amount of peptide immobilized on a bead surface was 
determined by comparing the peptide concentration of the unbound fraction (the 
remaining free peptide concentration after binding to the surface) to the starting 
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concentration through absorbance changes at 280 nm.  β-Gal was captured on 
the peptide-modified beads using the same protocol which immobilized the 
enzyme in the microwells, above. The amount of bead-immobilized β-Gal was 
measured by comparing the protein concentration of the unbound fraction to the 
starting protein concentration, determined at 280 nm. KM and Vmax (and thus kcat, 
using the total enzyme concentration) of β-Gal immobilized on peptide-modified 
beads were determined by fitting the activity vs. substrate concentration curves in 
the GraphPad program using the fitting equation of “Y=Vmax*X/(Km+X)”. 
Peptide mapping to β-Gal The specific regions at which the peptides 
YHNN and QYHH bind to β-gal were determined by reversible formaldehyde 
cross-linking, as described previously.8,12 200 µL of a 150 µM peptide solution 
was first conjugated to 100 µL of UltraLink iodoacetyl resin using the method 
described above. To promote cross-linking, the peptide-modified resin was 
incubated with 200 µL of 500 nM β-Gal for two hours. 200 µL of 1% 
formaldehyde (v/v), prepared in 1X PBS, was added to the enzyme-bound resin 
for 10 mins. Then, the formaldehyde solution was removed quickly by 
centrifugation. The resin was washed three times with 1 mM Glycine, pH 2.5 to 
remove enzyme that did not undergo cross-linking. Proteolytic digestion was 
performed by incubating the enzyme-bound resin with 34 nM Glu-c in ammonium 
bicarbonate buffer, pH 8.5, overnight at 37 °C. Then, the resin was washed again 
with Glycine, pH 2.5 to remove Glu-c and any fragments that did not undergo 
cross-linking. The formaldehyde cross-linking was reversed by incubating the 
resin with 20 µL nanopure water at 70°C overnight. Following cross-link reversal, 
100 µL of nanopure water was added to the resin to dissolve the free Glu-c-
digested peptide fragments. The solution was spun to the bottom of the spin-
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column and then dried, by evaporation, in a vacuum centrifuge. The dried sample 
was re-dissolved with 10 µL of 1:1 acetonitrile:H2O containing 0.1% trifluoroacetic 
acid and saturated R-cyano-4-hydroxycinammic acid matrix.  The sample was 
spotted on a standard MALDI-MS (Matrix-assisted laser desorption/ionization 
mass spectrometry) target plate, and analyzed using a Bruker Microflex MALDI-
MS. 
RESULTS AND DISCUSSION 
In previous chapters,  an approach for screening high-density peptide 
arrays was described to identify specific peptide sequences that anchor enzymes 
to surfaces and modulate their activity.10 To demonstrate the utility of this 
approach more generally for optimized enzyme immobilization, two 20-mer 
peptides, YHNNPGFRVMQQNKLHHGSC (referred to as YHNN) and 
QYHHFMNLKRQGRAQAYGSC (referred to as QYHH) were selected from a 
microarray of 10,000 peptides based on their ability to bind β-Gal and optimize its 
surface-immobilized activity (Table 6). These peptides were then synthesized 
and covalently conjugated to aminated microwells, modifying the surface and 
mediating the binding of β-Gal through specific peptide-enzyme interactions 
(Figure 52). As controls, two inhibitory peptides, RVFKRYKRWLHVSRYYFGSC 
(RVFK) and PASMFSYFKKQGYYYKLGSC (PASM), and one weak-binding 
peptide, EFSNPTAQVFPDFWMSDGSC (EFSN), were also used to modify 
aminated microwells (Table 7).  
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Table 6 Microarray data corresponding to selected peptides used for surface 
conjugation a. 
Peptide Sequence pI Enzyme activity (Norm.)
Enzyme binding 
(Norm.)
Surface specific 
activity (Norm.)
1 YHNNPGFRVMQQNKLHHGSC 9.3 92.3 37.8 10.9
2 QYHHFMNLKRQGRAQAYGSC 9.8 90.4 42.4 9.5
3 RVFKRYKRWLHVSRYYFGSC 10.3 0.9 50.3 0.08
4 PASMFSYFKKQGYYYKLGSC 9.4 2.3 63.9 0.16
5 EFSNPTAQVFPDFWMSDGSC 3.5 0.7 0.4 -  
a Peptides 1 and 2 were selected to promote strong activity when bound to β-Gal. 
Peptides 3 and 4 bind to β-Gal but result in very low enzyme activity. Peptide 5 
does not bind to β-Gal.  
 
Table 7 Normalized activity and affinity of β-Gal immobilized on modified 
surfaces a. 
 
a Types of surfaces: 1 and 2 are selected peptide-modified surfaces; 3 and 4 are 
control surfaces modified by inhibitory peptides; 5 is a control surface conjugated 
with a weak-binding peptide; 6-8 are the conventional surfaces used for covalent 
or noncovalent enzyme immobilization, defined as in Figure 52, legend. All of the 
data is normalized to that of the amine surface, 8.  
β-Gal immobilized on YHNN- and QYHH-surfaces exhibited much higher 
activity than β-Gal immobilized on control peptide-modified surfaces (Figure 56). 
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The relative specific activity of immobilized β-Gal was calculated for each surface 
by dividing the total bound enzyme activity by the total binding intensity. 
Conventional surface immobilization approaches were also tested including 
SMCC-activated (SMCC 6) and NHS-activated (NHS 7) covalent attachment, as 
well as noncovalent amine-surface attachment (Amine 8). YHNN- and QYHH- 
modified surfaces resulted in a specific activity of bound enzyme that was ~ 2-
fold greater than amine noncovalent binding and nearly 3-fold greater than NHS 
attachment. In addition, the YHNN- and QYHH-modified surfaces have the 
advantage of specifically associating with β-Gal in a protein mixture. This was 
shown by binding β-Gal in a solution containing 3% Bovine serum albumin (BSA). 
YHNN- and QYHH- modified surfaces showed 15-fold more bound enzyme 
activity than the amine surface and 20-fold more than the NHS surface (Figure 
57).  
In addition, YHNN- and QYHH-modified surfaces were also found to 
improve the thermal and pH stability of immobilized β-Gal. The thermal stability of 
bound β-Gal was ~ 16-fold greater on the peptide-modified surfaces than free 
enzyme in solution after incubating at 55 °C for one hour (Figure 58) and more 
than 2-fold better than enzyme immobilize to either the NHS or amine surfaces. 
Immobilization of β-Gal on YHNN- and QYHH-modified surfaces also shifted the 
pH optimum from pH 8 in free solution to 7 on the surface. Long-term enzyme 
stability to storage on surfaces was greatly improved on peptide-modified 
surfaces, particularly when peptide modification was combined with the use of a 
hydrogel (5% polyvinyl alcohol, PVA) coating. β-Gal immobilized in this way and 
stored dry for one week at room temperature retained ~35% of its original 
activity . In contrast, enzyme similarly immobilized and stored on amine surfaces 
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retained less than 5% activity and NHS surfaces retained ~14% (Figure 59).  If 
one considers both the increased binding capacity of the peptide-modified 
surfaces and their increased stability to storage, there was 20-fold more enzyme 
activity per surface area after storage on the peptide-modified surfaces than 
either the amine surfaces or the NHS surfaces, a significant factor in the 
commercial immobilization and storage of enzymes.  
 
   
 
Figure 56. Activity of β-Gal immobilized on different surfaces. 25 nM β-Gal is first 
incubated with modified microwells for one hour and then enzyme activity is 
measured at 25 °C as a function of time using 100 µM Resorufin β-D-
galactopyranoside as the substrate.  YHNN, QYHH, RVFK, PASM and EFSN 
represent β-Gal bound to various peptide-modified surfaces (see text). SMCC 
and NHS represent enzyme covalently bound via thiol and amine conjugation, 
respectively. AMINE represents enzyme bound noncovalently to an aminated 
surface.  
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Figure 57. Specificity of different types of surfaces for capturing β-Gal in a 
protein mixture. 25 nM β-Gal was mixed with 3 % BSA and then applied to these 
surfaces. The activity of each enzyme-bound surface was measured by adding 
100 µL of 100 µM RBG into each microwell.  
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Figure 58. (a) Normalized thermal stability of immobilized β-Gal on different 
surfaces. The thermal stability of immobilized β-Gal was measured by incubating 
the enzyme at a specific temperature between 25 °C and 60 °C for one hour and 
then assaying its activity. Note that the activity of β –Gal after exposure to high 
temperature is substantially enhanced when bound to the YHNN and QYHH 
peptide-modified surfaces. The activities of β-Gal at different temperatures were 
normalized to that at 25°C. (b) Normalized activity of β-Gal immobilized on 
peptide-modified surfaces as a function of pH. The solution pH dependence of 
the activity is shown in dark blue for comparison. The activities of β-Gal at 
different pHs were normalized to the maximum activity at optimal pH.  
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Figure 59. Long-term stability of β-Gal immobilized on different surfaces. The 
long-term stability of the enzyme was tested in two ways. One method used was 
to coat the enzyme-bound microwell with PVA, dry it and then store it at room 
temperature in this condition for a week (the second column for each sample). 
The other method used was to dry the enzyme-bound microwell without PVA 
coating and store it at room temperature for a week (the third column for each 
sample). The remaining enzyme activity after storage is assayed by adding 100 
µL of 100 µM RBG into each well. As shown in the figure, the peptide surfaces 
combined with PVA coating greatly maintain the enzyme activity after storage 
compared to the other surfaces.  
The apparent Kd values of the YHNN- and QYHH-modified surfaces were 
~ 5 nM and ~ 4 nM for β-Gal, respectively (Figure 60). The apparent kcat and Km 
constants for immobilized β-Gal were measured on peptide-modified iodoacetyl 
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resin, which has a large binding capacity and allows for the quantification of the 
absolute amount of bound enzyme (Figure 61).  kcat values were ~ 46 s-1 for the 
YHNN- surface and ~ 53 s-1 for the QYHH- surface, similar to the kcat of ~ 58 s-1 
under the same conditions for the free enzyme. The apparent Km values of β-Gal 
bound to the YHNN- and QYHH-modified surfaces were ~ 240 µM and 250 µM, 
respectively, compared ~ 130 µM for the free enzyme. The apparent increase in 
Km for the surface-bound enzyme may be due to slow diffusion of substrate 
molecules to the surface and local substrate depletion.11  
In Figure 62, peptide-protein binding sites for YHNN and QYHH were 
determined by proteolytic mapping using reversible formaldehyde cross-linking12. 
YHNN and QYHH both bound to the same protein fragments (419-447) at the 
subunit interface of β-Gal (Figure 63 and 64). β-Gal from E. coli is only active in 
its tetrameric form13, and it may be that YHNN and QYHH enhance the activity 
and stability of β-Gal by stabilizing its tetrameric structure.  
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Figure 60. The apparent dissociation constants of different surfaces determined 
by ELISA. All data is fitted using the program GraphPad and the fitting equation: 
Y=Bmax*X/(Kd + X), where  Bmax is the theoretical maximum binding level of  β-Gal.  
[*] For the SMCC- and NHS-surfaces, there is no real KD since this is a covalent 
conjugation with no dissociation equilibrium. In that case, the apparent KD is 
calculated from curve fitting and likely reflects the saturation of enzyme 
attachment to the NHS-surface.  
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Figure 61. Colored curves: Curve fit used to determine the apparent KM and kcat 
of β-Gal immobilized on YHNN- and QYHH-modified beads using an amount of 
bound enzyme equivalent to a solution enzyme concentration of ~ 150 pM. Black 
curve: fit used to determine KM and kcat for the free enzyme at 150 pM. The 
enzyme activities are measured as a function of the concentration of the 
substrate RBG, between 3 µM and 400 µM, at 25 oC. All data is fitted using the 
program GraphPad and the fitting equation: Y=Vmax*X/(Km+X). 
 
 
Figure 62. Proteolytic mapping of peptide binding to tetrameric β-Gal with 
binding regions circled. Each subunit is labeled with a unique color showing the 
symmetry of the β-Gal structure. The binding regions (amino acids 419-447) are 
highlighted in blue. 
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Figure 63. MALDI-TOF analysis of β-Gal crosslinked to YHNN-modified beads 
after Glu-c digestion. The upper figure is a YHNN-bead blank control and the 
lower figure is β-Gal crosslinked to YHNN-beads. The protein fragment analysis 
indicates that the main binding region between the enzyme and the YHNN-beads 
is located near the amino acid residues 419-447 (bottom table). Many of the 
digest fragments observed are actually from the same stretch of amino acid 
sequence but have different degrees of oxidation as a result of exposure to 
formaldehyde. 
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Figure 64. MALDI-TOF analysis of β-Gal crosslinked to QYHH-modified beads 
after Glu-c digestion. The upper figure is a QYHH-bead blank control and the 
lower figure is β-Gal crosslinked to QYHH-beads. The mapping data shows that 
the binding region of the peptide QYHH with β-Gal is near amino acid residues 
419-447, just as was observed for the peptide YHNN. This region of β-Gal is 
located near the interface between two subunits of the protein.  
Point-variant screening14,15 was applied to the YHNN peptide to improve 
both the affinity and activity of bound enzyme. 132 single-point variants, 
containing all substitutions of the amino acid set {Y, A, D, S, K, N, V, W}  in each 
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of the 17 randomized positions, were synthesized, printed on a microarray and 
analyzed for affinity and activity10. Figure 65a shows the binding level vs. activity 
of β-Gal for each single-point variant, normalized to the YHNN- lead peptide. 
Several variants increased both binding level and activity, (region ii), including 
variant V9Y (YHNNPGFRYMQQNKLHHGSC) which increased binding by 1.5-
fold and specific activity by nearly 3-fold compared to the YHNN- lead peptide 
(Table 8). V9Y conjugated to an aminated microwell increased both the binding 
and the specific activity of immobilized β-Gal by ~2-fold compared to YHNN.  
This corresponds to a total bound enzymatic activity on the V9Y-modified surface 
that is ~ 12-fold greater than the NHS surface and more than 5-fold greater than 
the amine surface (Figure 66). Combining two advantageous point mutations into 
a single peptide (e.g.V9Y and N13Y, Table 8) resulted in an increase in the 
affinity of the peptide for binding to β-Gal but did not significantly enhance the 
specific activity of bound enzyme compared to single-point variants. 
The library of single-point variants was also screened for enhanced 
thermal or pH stability of immobilized β-Gal. For thermal stability screening, 
enzyme was bound to microarrays containing the 132 single-point variants, at 
room temperature, and then the arrays were incubated at 55 °C for one hour and 
assayed for activity at room temperature. A few point variants improved the 
resulting activity of bound β-Gal by nearly 50% compared to the YHNN- lead 
peptide (Figure 65b, circled region, and Table 9).  pH stability was screened by 
incubating enzyme-bound arrays in buffers ranging from pH 6 to pH 9 for one 
hour and then assaying activity at the pH used for incubation. In Figure 65c, 
some variants were found to significantly improve the specific activity of bound β-
Gal at both low (pH 6) and high (pH 9) pH compared to the YHNN- lead peptide 
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(e.g. Q12A, YHNNPGFRVMQANKLHHGSC shows a 4.1-fold activity increase at 
pH 6 and a 2.8-fold increase at pH 9, Table 10).   
CONCLUSIONS 
A simple method for immobilizing enzymes through specific interactions 
with peptides anchored on surfaces has been developed. Peptides can be rapidly 
selected from microarrays and covalently conjugated to surfaces for capturing 
target proteins. Peptide-modified surfaces improve both the specific activity and 
stability of bound β-Gal compared to free enzyme or to conventional enzyme 
surface immobilization approaches. In addition, the affinity and activity of one of 
the peptide-modified surfaces was further improved by single-point variant 
screening. Variants were found that not only improved activity under normal 
conditions, but enhanced thermal stability, increased enzyme activity at extreme 
pH and improved the stability of the enzyme to storage in hydrogels. This 
approach should be applicable to the immobilization of a wide variety of enzymes 
on surfaces with optimized performance, and provides a potential mechanism for 
the patterned self-assembly of multiple enzymes on surfaces. 
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Figure 65. Point-variant screening of a 
lead peptide, YHNN. β-Gal was bound 
to a microarray containing 132 YHNN 
variants and its activity was measured. 
(a) The activity of bound β-Gal on 
microarrays as a function of the amount 
of enzyme bound to a particular variant 
feature at room temperature. (i) Variants 
with poor affinity and activity; (ii) 
Variants with stronger affinity and higher 
activity; (iii) Variants with stronger 
affinity but relative lower activity. All 
data is normalized to the binding and 
activity values for the lead peptide, 
YHNN. (b) Thermal-stability assay. β-
Gal was bound to the microarray 
containing YHNN variants as in (a) at 
room temperature, followed by 
incubation in phosphate buffer at 55 °C for one hour.  Enzyme activity was then 
assayed at room temperature. The selection region (circled) contains variants 
that bind to the enzyme with higher relative specific activity (the ratio of binding to 
activity) under thermal stress compared to YHNN (c) pH activity range assay. 
YHNN variant microarrays were bound to β-Gal in buffers with pHs ranging from 
6 to 9 for one hour and then assayed for activity at the pH of incubation.  
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Table 8 Selected point variants that improve the binding affinity and activity of β-
Gal on a microarray surface a. 
 
a Peptide 1 is the YHNN- lead peptide; Peptides 2-9 are selected single-point 
variants; Peptides 10-14 are combinations of two single-point variants. The 
combination of two selected single-point variants sometimes improves the affinity 
to β-Gal, but does little to enhance the specific activity of the bound enzyme. All 
data is normalized to the YHNN- lead peptide. 
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Table 9 Point variants that improve the thermal stability of bound β-Gal a.  
 
a All data is normalized to the YHNN lead peptide. 
 
Table 10 Point variants that modulate the optimal pH range of bound β-Gal a.  
 
a All data is normalized to the YHNN lead peptide. 
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Figure 66. Activity of β-Gal immobilized on different surfaces which were 
modified by the lead peptide (YHNN) and its point variants, respectively, as 
selected from microarray screening. (a) YHNN and 5 selected single-point 
variants were used to modify aminated microwell surfaces for capturing β-Gal. 3 
variants, R8Y, V9Y and N13Y showed improvement of total bound enzyme 
activity. The variant V9Y demonstrated the best enzyme immobilization 
performance: a roughly 2-fold improvement both in surface affinity and relative 
specific activity of the bound enzyme, and nearly a 5-fold improvement in total 
activity of the bound enzyme. (b) Total enzyme activity immobilized on the 
YHNN- and V9Y-modified surfaces compared to amine and NHS surfaces. (c) 
Binding and activity of β-Gal immobilized on surfaces modified by peptides. The 
relative β-Gal binding amount is determined by measuring the activity of APase 
conjugated streptavidin bound to the biotinlyted β-Gal. The enzyme activity is 
evaluated by adding 100 µL of 100 µM RBG into each microwell. 
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CHAPTER 6: COMMERCIALIZATION OF THE TECHNOLOGY 
ABSTRACT 
Efforts in commercializing the technology developed during the Ph.D 
study are described in this chapter. We have attempted to start a company 
named “NOVLOLATOR” to provide technology solutions for enzyme applications. 
The initial investigation of market and business strategy was performed to 
determine the appropriate commercial application of the technology. 
INTRODUCTION 
Commercial use of enzymes in the manufacturing processes is generally 
classified in terms of industrial use or specialty use. Industrial users are generally 
placed into three classes: technical, food and animal feed (Figure 67)1 with 
technical using as the largest portion including: detergent, starch, textile, fuel 
alcohol, leather and paper manufacture. Specialty users are mainly from 
pharmaceutical companies, diagnostics, research and biotechnology 
organizations, or involved in specialized organic synthesis. It is estimated that the 
global market value for enzymes will reach almost $6 billion dollars by 2011, with 
an annual growth of almost 8 percent.1 This growth will be driven by the 
increasing demand in the pharmaceutical, fine chemical, and bioethanol 
industries. Commercial enzymes are required to function in a variety of 
challenging conditions. Consideration of thermalstability, pH tolerance and 
manufacturing ease are examples of crucial components to enzyme performance 
and utility. The continued lowering of barriers to commercialization is essential for 
expanding the application of enzymes in commercial use. Examples of some of 
the main challenges to the successful commercial use of enzymes are: 
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 Inhibition of enzyme activity due to high concentrations of 
substrates and products. 
 Functional instability in the presence of other ingredients (e.g. 
tolerance to organic solvents). 
 Instability to temperature and non-native pH environments. 
 Lack of sufficient, economical enzyme immobilization techniques 
that allow for industrial re-use of enzymes.2  
 Lack of direct high throughput methods for the selection of 
catalytically active and stable enzymes. 
Many enzyme based applications and processes could be improved if 
there were a means to increase the activity of an enzyme or stabilize and 
maintain its catalytic activity over time. Most commercial enzymes are found by 
screening natural organisms or created by improving existing enzymes. Directed 
evolution is the most widely-used tool to generate stable and active enzymes 
under desired conditions. But in many cases, directed enzyme evolution 
consumes considerable time and money to generate the optimized mutant 
enzyme satisfying the requirements. A combination of rational design and 
directed evolution may be a more powerful tool to create new enzymes with 
desired function. Small molecules that can modulate enzyme function are also 
used to optimize enzyme activity under a given set of conditions, which may 
expand the use of enzymes. 
This chapter describes our efforts in exploring business opportunities in 
developing peptides or other small molecules that improve enzyme function for 
commercial use.   
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Figure 67. Enzyme use in Industry.1 
BUSINESS CONCEPT/STRATEGY 
Company Overview During my Ph.D study, I collaborated with another 
graduate student, Berea Williams, and have tried to start a small company 
named “NOVOLATORS” based on the technology described in the previous 
chapters. NOVOLATORS is a technology service company that provides 
solutions for enzyme applications. The company provides methods and solutions 
to improve the performance of enzymes under a large range of desired 
conditions (high temperature, low pH, etc.). Figure 68 is the logo design of the 
company. 
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Figure 68. The logo of the company. 
Business Opportunity Many enzyme based applications and processes 
could be improved if there were methods to increase or decrease the activity of a 
specific enzyme under a particular set of conditions.  In particular, being able to 
inhibit one enzyme in the presence of others, stabilizing and maintaining its 
catalytic activity over time, or enhancing its activity under nonnatural conditions 
(high temperature, low pH, etc.) could greatly increase the utility of enzymes for a 
variety of applications.                                                                                                                                  
NOVOLATORS utilizes the technology described in  the previous 
chapters to modulate enzyme under a wide range of desired conditions to 
improve the performance of an enzyme. Novel enzyme modulators have various 
applications in consumer products, biotechnology, the pharmaceutical industry 
and the medical diagnostic industry. They can be used to decrease amounts of 
enzymes needed, extend the range of enzymatic conditions, stabilize enzymes 
over time/temperature and modulate enzyme activity under desired conditions. 
Distinctive Competence NOVOLATORS’ technology has the 
advantages of rapid high throughput enzyme modification, extending the range of 
enzyme working conditions, applicability to many enzyme classes, lower R&D 
cost, shorter development time period and industrial compatibility. 
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Development Strategy NOVOLATORS will target many sectors of the 
enzyme industry including the detergent, fine chemical, bioethanol, and 
purification processes. These sectors make up a large portion of the enzyme 
market and have a very high demand for functional enzymes in harsh conditions. 
Furthermore, those sectors are not subjected to the Food and Drug 
Administration (FDA) guidelines, which will take years to process. 
Funding We have received $ 18, 000 from the Edson Student Entrepreneur 
Initiative at Arizona State University for initialing the business. 
MARKET ANALYSIS 
Market Structure The global demand for enzymes is estimated to be a 
$6 billion dollar industry in 2011.1 This growth will be driven by the increasing 
demand in the pharmaceutical, fine chemical, and bioethanol industries. The 
leading manufacturer of enzymes is Novozymes with 26% of the total enzyme 
market and 46% of the industrial enzyme market, and a net profit of ~$180 million 
in 2008. Other enzyme producers include Genencor, Danisco, Allergan, Roche, 
Genzyme, DSM and BASF, which share 36% of the market. Two main 
commercial consumers of enzymes are industrial and specialty markets. The 
industrial sector mainly uses enzymes in food, animal feed, and detergents. The 
specialty sector includes the pharmaceutical, fine chemical, and bioethanol 
industries, which use enzymes in disease detection, biotechnology research, 
organic synthesis, and purification processes. 
Potential Customer We will provide service to enzyme-consuming fields, 
like detergent (Dial @ Henkel), biofuel, surface-based catalysis and chemical 
production. The pharmaceutical and research enzyme fields are also potential 
markets.    
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Market Competitor Enzyme Companies like Novozyme and Genencor, 
are the main providers for commercial enzymes. Nonspecific enzyme stabilizers 
(PEG, glycerol, cellulose, etc.) are commonly used in enzyme products for 
stabilization. 
ENZYME TARGET 
In collaboration with Technology Service Venture Group (TVSG) and 
Arizona Technology Enterprises (AzTE), we conducted a study of the commercial 
enzymes and identified some potential targets.    
RESEARCH ENZYMES Taq DNA Polymerase was purified from the hot 
springs bacterium Thermus aquaticus around 1976, and became one of the most 
important discoveries in molecular biology. Currently, the world market for Taq 
polymerase is in the hundreds of millions of dollars3. There is a wide range of 
polymerase prices from the lowest of $0.1/unit to the highest of $1.0/unit. The 
average price for Taq polymerase used in academic research is ~ $ 0.3/unit.  
The thermostability of Taq DNA polymerase is the critical feature that 
facilitated the development of Polymerase Chain Reaction. The thermalstability 
of the Taq polymerase is listed in Table 11. Special care has to be taken to avoid 
loss of activity at high temperature or protein denaturation happened at room 
temperature storage. Recent DNA sequencing technology that involves the use 
of polymerase requires the immobilized polymerase on surface with strong 
activity and good stability at room temperature. Thereby, the high quality enzyme 
with stable activity at both room temperature and high temperature will be more 
welcomed to academic and industrial research.  If we develop peptide-modified 
beads for capturing polymerase with improved thermal stability, for example, 
extending the enzyme half life from 5 min to 50 min at 97.5 ºC, it will reduce the 
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amount of enzyme to ~ 10 - 20 % of the traditional use. It will use less 
polymerase for the same reactions than the traditional methods. 
 
Table 11. The thermal stability of Taq polymerase 
Reverse transcriptase is widely used in the detection of pathogen and 
disease diagnostics. The improvement on the thermal stability of the enzyme will 
reduce the secondary structure of mRNA and improve the detection accuracy. 
BioRed is trying to develop thermal-stable reverse transcriptase for its disease 
diagnostics. It is possible to use peptides to stabilize the enzymes at higher 
temperature and thereby improve the accuracy of mRNA reverse transcription 
assay.  
Restriction enzymes are enzymes that cut a DNA molecule at a particular 
place. They are essential tools for recombinant DNA technology. The enzyme 
"scans" a DNA molecule, looking for a particular sequence of usually four to six 
nucleotides. Once it finds this recognition sequence, it stops and cuts the strands. 
Although half life values differ greatly among enzymes, it is common procedure 
to keep the enzymes cold to avoid activity loss. The use of restriction enzymes 
continues to increase in biological and biotechnical research. Potential problems 
for the restriction enzymes are: low enzyme activity under the conditions of high 
glycerol and high pH; activity sensitive to organic solvents; product inhibition at 
high concentration of substrate DNA and poor stability that many enzymes simply 
stop working even under the best conditions after half an hour.  
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INDUSTRIAL ENZYMES Cellulase is a class of enzymes that catalyze 
the cellulolysis (or hydrolysis) of cellulose. Demand for Cellulase has been 
increasing rapidly, and it will become one of the most important enzymes for 
sustainable development of biofuels. The reason for this is the high abundance of 
its substrate cellulose (100 billion dry tons/year produced), which could be used 
to produce biofuel. The potential cellulase market has been estimated to be as 
high as $400 million per year if cellulases are used for hydrolyzing the available 
corn stover in the midwestern United States.4 This enzyme is relatively expensive 
and cost reduction must be achieved if it is to be used for commercial production. 
Genencor International and Novozymes Biotech claimed recently to greatly 
reduce the cost of cellulose by improving the production method and by 
improving enzyme activity. In order to have a sustainable technology, cellulases 
must be improved in several characteristics: higher catalytic efficiency on 
insoluble cellulosic substrates, increased stability at elevated temperature and 
certain pH levels, and higher tolerance to end-product inhibition. 
TEAM MANAGEMENT 
Berea Williams, Team Leader 
Berea entered graduate school in 2005 and graduated with her PhD in chemistry 
from Arizona State University. Her graduate education has used a highly 
interdisciplinary approach to solving fundamental problems in biochemistry 
research. Berea is also the president of the Biodeisgn Graduate Student 
Organization (BGSO) and leads a seminar series called “Careers Outside the 
Lab”.  
Jinglin Fu, Co-Team Leader 
Jinglin is a fourth year PhD graduate student in the Department of Chemistry and 
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Biochemistry and the Biodesign Institute at Arizona State University. His 
successful research in developing novel enzyme modulators has resulted in two 
provisional patents. Jinglin has extensive knowledge in enzymology and high 
throughput screening. He is very interested in translating fundamental research 
ideas into commercial products.  
MILESTONES FOR THE BUSINESS DEVELOPMENT 
Milestone 1 (4/1/2009 – 7/1/2009) We have prepared the business plan 
for “NOVOLATOR” for the application to the Edson Student Entrepreneur 
Initiative. 
Milestone 2  (7/1/2009 – 10/1/2009) We conducted the initial study of the 
market and suggested potential enzyme targets with high margin and which are 
used extensively, such as cellulase used in biofuels. We have contacted two 
potential investors/customers, Dial@Henkel and BioRed. Unfortunately, these 
investor/customers do not believe our product line is mature enough to invest in 
currently, however they do see potential in this field. 
Milestone 3 (10/1/2009 – 1/1/2010) We surveyed the use of commercial 
enzymes with the collaboration of the Technology Venture Service Group at ASU 
and concluded that the best fit market for our technology was enzymes used on 
surfaces, including bead-based catalysis, well-based catalysis and 
electrocatalytic enzymes. However, most commercial enzyme information in 
these areas is protected by the company either as patent or trade secret. 
Milestone 4 (1/1/2009-7/1/2010) We have decided to delay the start of 
the company, and perform additional experiments to demonstrate the technology, 
for example, improving the immobilized enzyme activity on peptide surfaces. It 
will make the technology more useful if we can combine the peptide selection 
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with the protein engineering. For example, it is possible to design new enzyme 
variants incorporated with peptide fusions selected from microarray. The variants 
may possess new properties that are modulated by the incorporated peptide 
minidomains.  
CONCLUSION 
We have decided to delay our effort to commercialize this technology until 
after the end of Edson student entrepreneur initiative project. There are a couple 
of issues: 
Entering the Market We have tried to determine which enzymes either are 
of interest to industry or are used by companies. However, most commercial enzyme 
information is protected by the company either as patent or trade secret. We 
discussed this with a senior scientist at Dial@Henkel, and he suggested that we 
continue to demonstrate the technology using widely known enzymes (which may 
not have high commercial margins) and then start more detailed collaborations and 
discussions with enzyme companies.  
Competing technology NOVOLATOR is based on a new technology using 
peptides to modulate enzyme function. The investor/customers (Dial) do not believe 
our product line is mature enough for investment, however they do see the potential 
for this field. The expensive cost of peptides is also a big limitation. There are 
established technologies for improving enzyme function, like directed evolution. We 
have not fully demonstrated the advantage of our technology over the conventional 
methods in the practical application. It will be more promising to industry if we can 
combine the selection of peptide ligands with protein engineering to create new 
enzyme mutants with optimized activity and stability (discussed more in the next 
chapter). 
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Funding We have received $ 18, 000 from the Edson Student Entrepreneur 
Initiative at Arizona State University for initialing the business. We have considered 
applying for SBIR/STTR grants, but there are limitations in terms of our student status. 
Also one of the founders, Berea William, decided to work at Dial after her graduation.  
Patent Ownership After several discussions with AzTE and advisors from 
Law school, we have figured out that ASU owns the patents rather than the inventors 
themselves (ASU paid money for the patent application). If we want to start a 
company based the technology patented, the licensing of the technology from ASU is 
required. 
Overall, it is an excellent experience for Ph.D students to think about 
commercializing the technology that they have been developed during their study. I 
appreciate the funding support from Edson program which made it possible for us to 
start the business investigation and trials.  As an Edson fellow, I have received some 
basic entrepreneurial education in the Launch Prep Entrepreneur Course. The initial 
investigation involves market analysis, business strategy development, contact with 
potential customers, communication with business and law consultants, and exploring 
funding opportunities. I have benefited greatly from these experiences which have 
broadened the scope of my study beyond fundamental research.  
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suggestions; Neal Woodbury and Mike Mobley as the advisors for our project and 
Peter He from Dial@Hekel for the helpful discussions. 
 
138 
REFERENCES 
(1)       Cherry, J. R.; Fidantsef, A. L. Curr. Opin. Biotechnol. 2003, 14, 438-443. 
(2)       Sheldon, R. A. Adv. Synth. Catal. 2007, 349, 1289-1307. 
(3)       Taq DNA Polymerase: Profile of an Indispensable Reagent, the Science 
Advisory Board, 
http://www.scienceboard.net/studies/studies.asp?studyId=121 
(4) Percival Zhang, Y. H.; Himmel, M. E.; Mielenz, J. R. Biotechnol. Adv. 
            2006, 24, 452-481. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
139 
CHAPTER 7: CONCLUSIONS AND FUTURE CONSIDERATIONS 
CONCLUSIONS 
In this dissertation, a simple and general method of discovering enzyme 
modulators has been developed by performing parallel measurements of enzyme 
binding and activity on peptide microarrays. Chapter 1 introduced enzyme theory 
and the importance of discovering enzyme modulators for therapeutics and 
industrial applications. The microarray platform represents a powerful tool for 
high-throughput screening of enzyme binding to small molecules, and profiling 
enzyme activity.   
Chapter 2 described the development of polymer-coated microarrays for 
monitoring enzymatic activity. Viscous poly vinyl alcohol (PVA) is an ideal 
medium to restrict molecule diffusion with a simpler fabrication process 
compared to microwell or microdroplet arrays. PVA has good properties for 
biological and imaging application, such as optical transparency and non-
fluorescence, as well as low toxicity. It will generate a flat film if dried quickly and 
thereby stop all reactions at the same time. There are many other viscous 
hydrogels, like agarose or polyacrylamide, but they either have autofluorescence 
or shrink during the drying process. Slower diffusion was achieved by adding 
anti-product antibodies into the PVA layer, which formed large complexes with 
corresponding product molecules and diffused more slowly than product 
molecules alone. We realized that the using a fluorescent substrate analogue 
limited this technology from achieving broader application. To overcome that 
problem, I developed a cascade reaction system within the PVA layer that was 
able to convert nonfluorescent products into fluorescent signals. The screening of 
dehydrogenase activity was presented as a demonstration.   
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In Chapter 3, it was able to identify several peptides that modulated 
enzyme function, using the polymer-coated array methodology that I had 
developed. It was not only possible to identify enzyme inhibitors; peptides that 
enhanced enzyme activity were also identified. Enzymes can be assayed on 
microarrays under many conditions, such as pH, temperature and organic 
solvent in order to discover molecules that will promote or inhibit enzyme activity 
in varied environments. This approach was demonstrated by identifying peptides 
that improve the thermal stability of enzymes screened on microarrays at high 
temperatures. Some of the inhibitory peptides selected from microarrays were 
also able to inhibit enzymes in solution, exemplifying the transfer of function from 
surface to solution.  
Chapter 4 described the mechanism of peptide inhibition of β-Gal in 
solution. Some peptides were able to inhibit β-Gal in solution with IC50 values 
ranging from 1 μM to 30 μM. These peptides exhibited noncompetitive kinetics in 
the apparent Michaelis constants, which meant that the peptides inhibited the 
enzyme not by binding to the active site. Next, it was found that the enzyme and 
detergent concentration affected the peptide inhibition of β-Gal, which suggested 
that peptides might aggregate with enzymes. Aggregation of peptides with 
enzymes was verified using dynamic light scattering and fluorescence correlation.  
It is also possible to design peptide pairs that can switch enzyme function based 
on stabilizing or destabilizing the aggregation of enzymes. It will be of therapeutic 
interest if the peptides can induce specific aggregation with target enzymes or 
disaggregate protein complexes.  
Protein-ligand binding may be affected by the fluorophores used to label 
the protein. First, the fluorophore itself or the fluorophore-protein interface may 
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create a binding site for some peptides (e.g. hydrophobic sequences), thereby 
driving the whole protein binding with the peptides. These selected peptides 
generally do not bind to the non-labeled protein and result in false positives. In 
my experience, such sequences generally contain multiple continuous 
hydrophobic residues or positive-charged residues, such as WWW, KKK, RRR or 
HHH. Second, labeled fluorophores may dramatically change the surface pI of a 
protein. Many fluorophores contain negatively-charged groups, like carboxyl 
group. Most labeling molecules are conjugated to lysine residues which 
neutralize the positively-charged amine on the side chain. Those make protein 
more negatively-charged, driving the pI to be more acidic. Ideally, the non-
labeling detection methods, like Surface Plasmon Resonance or Mass 
Spectrometry, will make microarray selection more efficient and accurate. An 
alternative approach is to use a secondary antibody for detection, or to label the 
protein with a low ratio of fluorophore (~ 1:1). 
In chapter 4, positively-charged residues, such as K and R, were found to 
be crucial for inhibiting β-Gal through a detailed sequence analysis of two 
selected 20-mer peptide inhibitors and the point-variant screening of a 10-mer 
peptide. In chapter 5, point-variant screening of a 20-mer peptide that bound to 
β-Gal and enhanced its thermal activity were also performed to understand the 
contribution of amino acid residues. In Figure 69a, the heat map revealed that 
most substitutions at positions of Y1, F7, R8 and H17 resulted in an affinity 
decrease of peptide binding to β-Gal, and substitutions at H2 resulted in an 
increase in peptide binding to the enzyme. It suggested that the residues Y1, F7 
and R8 were important for binding to β-Gal. Histidine (H) showed contradictory 
results for H2 and H17, but binding decreased for the substitutions at H17, 
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perhaps due to its close proximity to the C-terminal immobilized surface. It was 
also observed that substitutions of the YHNN lead peptide with K and D resulted 
in decreased peptide binding to the enzyme. Aspartate (D) is a negatively-
charged residue; it has been observed by others that negatively- charged 
residues (D and E) may decrease the binding of a peptide with an enzyme.1  
In Figure 69b, the heat map of specific activity revealed that most 
substitutions at positions F7, R8 and V10 resulted in an increase in bound 
enzyme activity. This suggested that those three residues inhibit the activity of 
the bound enzyme. The key role of R in inhibiting enzyme activity that has been 
observed here, was also consist with results obtained in Chapter 4. The 
substitutions at Y1 and H2 caused a decrease in enzyme activity, suggesting that 
Y1 and H2 were important for maintaining the activity of the bound enzyme. 
Interestingly, H2 showed a negative contribution to the binding of the peptide to 
the enzyme in Figure 69a, but a positive contribution to the activity of the bound 
enzyme. A similar contrary behavior between enzyme binding and activity was 
also observed for substitutions at F7 and R8.  
From the above study, it is concluded that the hydrophobic residues F 
and W, the positive-charged residue R and the hydrophilic residue Y may 
generally increase the affinity of peptide binding to a protein. The negatively-
charged residues D and E may generally decrease the affinity of peptide binding 
to a protein. For the activity of a peptide-bound enzyme, H, Y, W and A may be 
important for maintaining or improving enzyme activity. The positively-charged 
residues R and K often inhibit the activity of peptide-bound enzymes. It should be 
possible to select peptides with desired function (e.g.inhibit or promote enzyme 
activity from a more narrow amino acid set) 
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Figure 69. Heat map of single-point variant screening of YHNN for (a) binding to 
β-Gal and (b) specific activity of bound enzyme. All the single-point variants were 
printed on the microarray with three replicates of each sequence. A standard 
enzyme assay on the array was performed as described in Chapter 2. The 
specific activity of enzyme that bound to variants was calculated through dividing 
the total bound enzyme activity by enzyme binding intensity. All data was 
normalized to the binding and specific activity values of β-Gal bound to the lead 
peptide. Each data is the average of at least three runs 
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Chapter 5 described the use of selected peptides to immobilize enzymes 
on solid surfaces. There are several advantages of using peptides for surface-
based catalysis. First, peptides generally have lower affinities in solution, with 
protein binding dissociation constants (KD) ranging from 1 μM to more than 100 
μM. The affinity of peptide-modified surfaces for a particular protein can be 
improved by more than 1000-fold with apparent KD values of ~ a few nM, due to 
the avidity effect created by the high density of ligands. Second, peptides 
screened from microarrays exhibit the ability to modulate enzyme activity on the 
array surface. It is relatively easy to use this approach to select peptides that 
work as desired on a surface (even a surface somewhat different from the one 
that the original selection was performed on), compared to the process of 
selecting peptides on surfaces and then trying to use them in solution. Third, 
enzymes immobilized on peptide surfaces exhibited high activity and stability. In 
one example, it was possible to preserve enzyme activity for more than a week 
under dry conditions by immobilizing the enzyme on peptide surfaces coated with 
PVA polymer. This facilitates the transportation and storage of enzyme-related 
products. Last, there are well-established solid-phase peptide synthesis methods. 
Therefore, it is possible to produce peptide surfaces (like beads) in large 
quantities so that our peptide modulators may be combined with these synthesis 
technologies for commercial applications. 
Chapter 6 described my effort in commercializing the technology in 
collaboration with another graduate student. After the initial market analysis and 
contact with potential customs, my collaborator and I determined that additional 
development and demonstration of the technology were required before entering 
the enzyme market. 
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Future Considerations 
Screening enzyme activity on polymer-coated microarrays provides a 
simple, high-throughput and general method to discover enzyme modulators. 
Modifying the array-coating polymer with the ability to sense enzyme activity 
would simplify the technology and broaden the potential applications. In our 
current method, enzyme substrate is mixed with PVA for sensing enzyme activity. 
If the PVA or another coating polymer were to be modified with substrate 
(covalently linked), the product molecules generated from catalytic reactions 
would be trapped by the PVA with little diffusion. One possibility is to modify PVA 
or PVA derivatives with NAD+ for dehydrogenase detection. Poly acrylic acid, 
poly lysine, poly acrylamide2 and DNA gel3 are interesting polymers that can be 
modified with multi-functional groups or small molecules that will react with 
enzymes immobilized on array surfaces.  
Another interesting future improvement is the design of enzyme variants 
that have the peptide fusions selected from microarrays incorporated genetically 
in their DNA sequences, creating a protein-peptide fusion. Some peptides have 
been shown to improve enzyme activity and stability under many conditions, for 
example, stabilizing an enzyme at high temperature or shifting the optimal pH. 
We also showed the enzyme was irreversibly inhibited by crosslinking the 
inhibitory peptide with enzyme in Chapter 4.  
If the selected peptides can be engineered into either the N- or C- termini 
of wild-type enzymes, as fusions, the variants may possess new properties that 
are modulated by the incorporated peptide minidomains. In this way, it may be 
possible to create enzyme variants that are active under user-desired conditions 
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(e.g temperature, pH and organic solvent) by incorporating the fusion peptides 
selected from the microarray. This approach would be more interesting to the 
biocatalysis industry where they need more stable and active enzymes in their 
production process, but do not want to both produce an enzyme and a peptide.  
Finally, it may be possible to utilize selected, enzyme-specific peptide 
ligands to immobilize multi-enzyme cascade systems on surfaces. It has been 
known that many enzymes involved in the cellular metabolism have highly 
controlled position and orientation within the cell membrane. This is thought to 
facilitate multistep reactions by enhancing substrate transfer efficiency between 
component enzymes.4-6 It would be of great interest to design artificial catalysis 
systems that mimic cellular multi-enzyme cascades such that their catalytic 
efficiencies are maximized. Peptides have demonstrated the potential to anchor 
proteins on surfaces and control their orientations as well as optimize their 
activities and stabilities. If multiple peptide/enzyme pairs are selected, the 
peptides can be covalently attached to a surface or scaffold and serve as 
anchors for capturing target enzymes in controlled orientations. As such, 
wherever a particular binding peptide is placed, its enzyme partner will bind. This 
provides the basis for a self-assembling system that allows one to create enzyme 
cascades, on solid surfaces, that are optimized for maximal function under 
particular reaction conditions (e.g., temperature, pH, prolonged storage) and to 
catalyze reaction pathways by assembling several enzymes with defined spatial 
relationships (as shown in Figure 70). 
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Figure 70. Self-assembly of (a) a multi-enzyme system on a solid surface with 
homogenous orientation but random distribution and (b) a multi-enzyme cascade 
on a DNA nanostructure with precisely-controlled orientation and position.  
Personal Experience 
I’d like to complete this story by telling about my graduate research 
experiences. Initially, I planned to perform two research projects, developing a 
peptide catalyst and selecting a peptide transformer (see below). In order to 
select candidates that catalyze hydrolysis reactions from a microarray containing 
10,000 peptides, I had to think of a way to slow down molecular diffusion on 
surfaces to enable high-throughput screening of peptide libraries on the 
microarray platform. After several trials, I chose poly vinyl alcohol (PVA) as the 
coating to be used in my experiments. The model reaction was the hydrolytic 
reaction of Fluorescein di-β-D-galactopyranoside (FDG) which produces strong 
fluorescence after hydrolysis.  
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The objective of the peptide transformer project was to use peptides to 
mimic the binding of important biomolecules with proteins and replace expensive 
drug molecules with cheaper peptides (e.g. mimicking sugars). I attempted to use 
target molecules to block the binding of peptides with corresponding proteins on 
microarrays, hypothesizing that  blocked peptides might bind to the same protein 
sites as the target molecules. Competitive inhibition of β-galactosidase (β-Gal) 
with phenylethyl thio-beta-D-galactoside (PETG) was one model system that I 
had planned to mimic. Both projects were in the very early stages of 
development, and Neal and Stephen gave me the freedom to try various ideas 
for troubleshooting.   
After about half a year of research, I found it very hard to differentiate 
between the autofluorescence from the peptides themselves and the signals 
produced from the hydrolysis of the substrate. I needed a positive control to tell 
me what the real hydrolysis reaction would look like on the microarrays. I came 
up with an idea to perform β-Gal assays on PVA-coated microarrays since I knew 
that the enzyme would bind to many peptides on the arrays and that it could 
catalyze the hydrolysis of FDG. I discussed the idea with Neal and Stephen, and 
they both encouraged me to try it. Therefore, I did a very simple test to coat the 
β-Gal-bound array slides with PVA polymer containing FDG. Surprisingly, some 
enzyme-bound features exhibited strong fluorescence after the treatment. After 
several brainstorming discussions with Neal and Stephen, I felt that it would be 
more interesting to identify enzyme modulators by performing enzyme assays on 
the polymer-coated arrays. Over the next four years, I focused my research on 
developing polymer arrays for exploring peptide space to find enzyme 
modulators, as described in my dissertation.  
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Later, I realized how lucky I was during those initial trials. First, I was able 
to combine the two initial projects into a new and interesting idea. The peptide 
catalyst project provided a polymer coating method for monitoring catalysis. The 
peptide transformer project taught me a lot about  enzymology and performing 
enzyme binding assays on peptide arrays. Second, β-Gal is a very stable and 
active enzyme with strongly fluorescent substrates. Early on, I washed the 
enzyme-bound microarrays with water, not buffer solution. It is very likely that I 
could not see much catalytic activity on the arrays because all of the enzymes 
were dead. But some peptide-bound enzymes survived the tough water washing 
procedure and drying steps, and still exhibited activity after coating with PVA 
polymer containing substrates. (My ‘mistake’ also demonstrated the power of 
peptide modulators to maintain enzyme activity in very harsh conditions).   
It is also very important that my advisors, Neal and Stephen, gave me the 
freedom to try my own ideas and encouraged me to follow those thoughts that 
seemed promising. When I presented new ideas, they seldom made “YES” or 
“NO” judgments. Instead, they used their experience to help me define the 
possible problems and applications. I have benefitted greatly from those 
insightful and friendly discussions.  
In the end, I’d like to say, SCIENCE always gives people surprises and 
gifts. It will convey, bear great fortune if one dares to try with careful observation, 
critical thinking and hard work.  
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